


ROYAUME DE BELGIQUE

MINISTRE DES AFFAIRES ECONOMIQUES

ADMINISTRATION DE LA POLITIQUE COMMERCIALE




Il est certifié que les annexes à la présente sont la copie fidèle de documents que détient l'Office de la Propriété Industrielle.

Bruxelles, le 19. -1- 2004

Pour le Conseiller de l'Office
de la Propriété industrielle

Le fonctionnaire délégué,

PETIT M.
Conseiller adjoint



PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

PCT REQUEST

1/7

ABL-005-PCT2

Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

0	For receiving Office use only	
0-1	International Application No.	PCT / BE 03 / 00 20 6
0-2	International Filing Date	01 DEC 2003 (01-12-2003)
0-3	Name of receiving Office and "PCT International Application"	RO/BE - INTERNATIONAL APPLICATION
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.07.2003)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	Intellectual Property Office (Belgium) (RO/BE)
0-7	Applicant's or agent's file reference	ABL-005-PCT2
I	Title of invention	THERAPEUTIC POLYPEPTIDES, HOMOLOGUES THEREOF, FRAGMENTS THEREOF AND FOR USE IN MODULATING PLATELET MEDIATED AGGREGATION
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	ABLYNX N.V.
II-5	Address:	Technologiepark 4 B-9052 Zwijnaarde Belgium
II-6	State of nationality	BE
II-7	State of residence	BE
II-8	Telephone No.	+32 9 261 06 20
II-9	Facsimile No.	+32 9 261 03 28
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	SILENCE, Karen
III-1-5	Address:	Jean Tombeurstraat 21 B-3090 Overijse Belgium
III-1-6	State of nationality	BE
III-1-7	State of residence	BE

PCT REQUEST

ABL-005-PCT2

Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent.
IV-1-1	Name (LAST, First)	BRANTS, Johan, Philippe, Emile
IV-1-2	Address:	De Clercq, Brants & partners E. Gevaertdreef 10a B-9830 Sint-Martens-Latem Belgium
IV-1-3	Telephone No.	+32 9 280 23 40
IV-1-4	Facsimile No.	+32 9 280 23 45
IV-1-5	e-mail	info@dcbpntent.com
IV-2	Additional agent(s)	additional agent(s) with same address as first named agent
IV-2-1	Name(s)	DE CLERCQ, Ann; VIAENE, Ann
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

PCT REQUEST

ABL-005-PCT2

Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI-1	Priority claim of earlier regional application	
VI-1-1	Filing date	10 January 2003 (10.01.2003)
VI-1-2	Number	03447005.4
VI-1-3	Regional Office	EP
VI-2	Priority claim of earlier international application	
VI-2-1	Filing date	23 June 2003 (23.06.2003)
VI-2-2	Number	PCT/EP03/06581
VI-2-3	PCT receiving Office	EP
VI-3	Priority claim of earlier international application	
VI-3-1	Filing date	08 July 2003 (08.07.2003)
VI-3-2	Number	PCT/EP03/07313
VI-3-3	PCT receiving Office	EP
VI-4	Priority claim of earlier international application	
VI-4-1	Filing date	07 November 2003 (07.11.2003)
VI-4-2	Number	PCT/BE03/00191
VI-4-3	PCT receiving Office	BE
VI-5	Priority document request The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as Item(s):	VI-4
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)
VII-2	Request to use results of earlier search; reference to that search	
VII-2-1	Date	10 January 2003 (10.01.2003)
VII-2-2	Number	03447005.4
VII-2-3	Country (or regional Office)	EP

PCT REQUEST

ABL-005-PCT2

Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

VII-3	Request to use results of earlier search; reference to that search		
VII-3-1	Date	08 July 2003 (08.07.2003)	
VII-3-2	Number	PCT/EP03/07313	
VII-3-3	Country (or regional Office)	EP	
VII-4	Request to use results of earlier search; reference to that search		
VII-4-1	Date	23 June 2003 (23.06.2003)	
VII-4-2	Number	PCT/EP03/06581	
VII-4-3	Country (or regional Office)	EP	
VII-5	Request to use results of earlier search; reference to that search		
VII-5-1	Date	07 November 2003 (07.11.2003)	
VII-5-2	Number	PCT/BE03/00191	
VII-5-3	Country (or regional Office)	EP	
VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	1	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	

VIII-4-1	<p>Declaration: Inventorship (only for the purposes of the designation of the United States of America)</p> <p>Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America:</p>	<p>I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.</p> <p>This declaration is directed to the international application of which it forms a part (if filing declaration with application).</p> <p>I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.</p> <p>I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Applications," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.</p>
VIII-4-1 -1	Prior applications:	<p>03447005.4, EP, 10 January 2003 (10.01.2003)</p> <p>PCT/EP03/06581, EP, 23 June 2003 (23.06.2003)</p> <p>PCT/EP03/07313, EP, 08 July 2003 (08.07.2003)</p> <p>PCT/BE03/00191, BE, 07 November 2003 (07.11.2003)</p>

PCT REQUEST

ABL-005-PCT2


Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

		<p>I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p>
VIII-4-1 -1-1	Name:	SILENCE, Karen
VIII-4-1 -1-2	Residence: (city and either US State, if applicable, or country)	Overijse, Belgium
VIII-4-1 -1-3	Mailing address:	Jean Tombeurstraat 21
VIII-4-1 -1-4	Citizenship:	BE
VIII-4-1 -1-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
VIII-4-1 -1-6	Date: (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	

PCT REQUEST

ABL-005-PCT2

Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	7	-
IX-2	Description	93	-
IX-3	Claims	5	-
IX-4	Abstract	1	EZABST00.TXT
IX-5	Drawings	17	-
IX-7	TOTAL	123	
	Accompanying items	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	✓	-
IX-17	PCT-EASY diskette	-	Diskette
IX-19	Figure of the drawings which should accompany the abstract		
IX-20	Language of filing of the international application	English	
X-1	Signature of applicant, agent or common representative		
X-1-1	Name (LAST, First)	BRANTS, Johan, Philippe, Emile	

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	01 DEC 2003 (01-12-2003)
10-2	Drawings:	
10-2-1	Received	RECEIVED
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

PCT (ANNEX - FEE CALCULATION SHEET)

ABL-005-PCT2

Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only			
0-1	International Application No.	PCT/BE03/00206		
0-2	Date stamp of the receiving Office			
0-4	Form - PCT/RO/101 (Annex) PCT Fee Calculation Sheet			
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.07.2003)		
0-9	Applicant's or agent's file reference	ABL-005-PCT2		
2	Applicant	ABLYNX N.V., et al.		
12	Calculation of prescribed fees	fee amount/multiplier	Total amounts (EUR)	
12-1	Transmittal fee T	⇒	40	
12-2-1	Search fee S	⇒	945	
12-2-2	International search to be carried out by	EP		
12-3	International fee			
	Basic fee (first 30 sheets) b1	444		
12-4	Remaining sheets	93		
12-5	Additional amount (X)	10		
12-6	Total additional amount b2	930		
12-7	b1 + b2 = B	1,374		
12-8	Designation fees			
	Number of designations contained in international application	98		
12-9	Number of designation fees payable (maximum 5)	5		
12-10	Amount of designation fee (X)	96		
12-11	Total designation fees D	480		
12-12	PCT-EASY fee reduction R	-137		
12-13	Total International fee (B+D-R) I	⇒	1,717	
12-14	Fee for priority document			
	Number of priority documents requested	1		
12-15	Fee per document (X)	0		
12-16	Total priority document fee P	⇒	0	
12-17	TOTAL FEES PAYABLE (T+S+I+P)	⇒	2,702	
12-19	Mode of payment			

VALIDATION LOG AND REMARKS

13-2-1	Validation messages Request	Green? The title of the invention shall be short and precise. Please verify.
--------	--------------------------------	--

PCT (ANNEX - FEE CALCULATION SHEET)

ABL-005-PCT2

Original (for SUBMISSION) - printed on 01.12.2003 04:27:25 PM

13-2-7	Validation messages Contents	Yellow! The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
		Green? Figure of the drawings which should accompany the abstract not specified. Please verify.
		Green? Priority 1. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
		Green? Priority 2. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed).
		Green? Priority 3. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
13-2-8	Validation messages Fees	Green? Please confirm that fee schedule utilized is the latest available
13-2-9	Validation messages Payment	Yellow The Payment page has not been completed.

The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF A1 domain, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation

**THERAPEUTIC POLYPEPTIDES, HOMOLOGUES THEREOF, FRAGMENTS THEREOF
AND FOR USE IN MODULATING PLATELET-MEDIATED AGGREGATION**

BACKGROUND TO THE INVENTION

5 Upon damage to a blood vessel, subendothelial structures are exposed that mediate platelet adhesion through interaction with von Willebrand factor (vWF). vWF forms a bridge between collagen within the damaged vessel wall and the platelet receptor glycoprotein Ib (gplb), an interaction especially important under high shear conditions, leading to the formation of a haemostatic plug and thus preventing excessive bleeding (Bennett S, Thromb Haemost 10 (2001) Mar;85(3):395-400). During normal haemostasis, these processes lead to wound healing of the damaged blood vessel wall. In pathological conditions however, excessive platelet function may lead to thrombus formation. The vWF subunit is composed of several homologues domains each covering different functions. vWF interacts through its A3 domain with fibrillar collagen fibers and through its A1 domain with the platelet receptor gplb. Under 15 normal conditions platelets and vWF do not interact. However, when vWF is bound to collagen at high shear rate, it is believed to undergo a conformational change allowing its binding with the platelet receptor gplb. This reversible adhesion allows platelets to roll over the damaged area, which is then followed by a firm adhesion through the collagen receptors on the platelets (gpla/IIa, gpVI, gpIV, p65, TIIICBP) resulting in platelet activation. This leads 20 to activation of the gpIIb/IIIa receptor, fibrinogen binding, and finally to platelet aggregation.

Platelet aggregation inhibitors have been isolated from blood sucking organisms such as leech. Saratin, derived from leech *Hirudo medicinalis* is described in WO 02/15919 A2 and in Cruz CP *et al* ref. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, 25 decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. Journal of Vascular Surgery, 2001, 34: 724-729 and in Smith TP *et al*, Saratin, an inhibitor of collagen-platelet interaction, decreases venous anastomotic intimal hyperplasia in a canine dialysis access model, Vasc Endovascular Surg. 2003 Jul-Aug;37(4):259-69.

30 Antibody-based therapeutics have been developed, some of which are currently used in therapy.

Abciximab (Chimeric 7E3 Fab; ReoPro; US 6,071,514, EP 0 882 453), the Fab fragment of the mouse human chimeric antibody 7E3 which inhibits ligand binding to the platelet gpIIb/IIIa

receptor, was approved for human use as adjunctive therapy to prevent ischemic complications of percutaneous coronary interventions in December 1994. The principle safety issue with gp IIb/IIIa inhibitors is the risk of bleeding, as the potent anti-platelet effect of these drugs may adversely affect haemostasis.

5

A murine monoclonal antibody was developed against vWF A1 domain (US 2002/0028204 A1 ; US 6,280,731 and in WO 00/10601). The *in vivo* efficacy is described in Kageyama S, et al.: "Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis", *Eur J Pharmacol.* 2002 May 17;443(1-3):143-9, and in "Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs". *Thromb Res.*, 2001 Mar 1;101(5):395-404. and in "Anti-human von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs". *Arterioscler Thromb Vasc Biol.* 2000 Oct;20(10):2303-8). AJvW-2 inhibited high shear stress induced aggregation of human platelets and had no effect on low shear stress induced platelet aggregation.

15

The effects in baboons of a murine antibody 82D6A3 raised against the A3 domain of human vWF, are disclosed in WO 02/051351, and Dongmei Wu *et al*, "Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of *in vivo* arterial platelet thrombus formation in baboons". *Hemostasis, thrombosis and vascular biology*, 2002, 99: 3623-3628.

20

Antibody 6B4 is a monoclonal antibody (MoAb) raised against purified human gplb. MoAb 6B4 inhibits both ristocetin- and botrocetin-induced, vWF-dependent human platelet agglutination. MoAb 6B4 furthermore blocks shear-induced adhesion of human platelets to collagen I. When injected into baboons, intact IgG and its F(ab')(2) fragments caused almost immediate thrombocytopenia, due to the bivalency of F(ab')(2) which mediates platelet crosslinking, or Fc:Fc receptor interactions which mediate activation of platelet aggregation (WO 0110911; Cauwenberghs N. *et al*, *Arteriosclerosis, Thrombosis and Vascular biology*, 2000, 20: 1347 and see, for example, Cadroy Y *et al*, *Blood*, 1994, 83: 3218-3224, Becker BH *et al*, *Blood*, 1989, 74: 690-694, Ravanat C. *et al*, *Thromb. Haemost.* 1999, 82 : 528a abstract). Platelet deposition onto collagen-rich bovine pericardium was inhibited when Fab fragments were injected into the baboons before a thrombus was generated. However, when

25

30

the Fab fragments were injected after a thrombus was allowed to form, no inhibition of further thrombosis was observed. The yields of expression of said Fab molecules are very low and the method of production is very labour intensive.

5

THE AIMS OF THE PRESENT INVENTION

An aim of the present invention is to provide polypeptides comprising one or more single domain antibodies directed towards vWF, vWF A1 domain, vWF A3 domain, gplb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. It is a further aim to provide methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation

15

SUMMARY OF THE INVENTION

Single domain antibodies have been made which specifically recognize target molecules involved in the first and subsequent steps of platelet aggregation. This results in anti-thrombotic agents which are more efficacious and safer.

20

One embodiment of the present invention is a polypeptide construct comprising:

- at least one single domain antibody directed against any of vWF, vWF A1 domain, vWF A3 domain, gplb, or collagen.

25

Another embodiment of the present invention is a polypeptide construct as described above, further comprising at least one single domain antibody directed against one or more serum proteins.

30

Another embodiment of the present invention is a polypeptide construct as described above wherein said at least one serum protein is any of serum albumin, serum immunoglobulins, thyroxine-binding protein, transferrin, or fibrinogen or a fragment thereof.

Another embodiment of the present invention is a polypeptide construct as described above, wherein at least one single domain antibody directed against one or more serum proteins corresponds to a sequence represented by any of SEQ ID NO: 16 to 19 and 49 to 61.

- 5 Another embodiment of the present invention is a polypeptide construct as described above corresponding to a sequence represented by any of SEQ ID NOs: 13 to 15 and 42 to 45.

Another embodiment of the present invention is a polypeptide construct as described above wherein at least one single domain antibody is a humanised sequence.

10

Another embodiment of the present invention is a polypeptide construct as described above wherein at least one single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 38 to 41 and 42 to 45

- 15 Another embodiment of the present invention is a polypeptide construct as described above corresponding to a sequence represented by any of SEQ ID NOs: 8 to 12, 20 to 22, 32 to 34, and 42 to 47.

- 20 Another embodiment of the present invention is a polypeptide construct as described above wherein at least one single domain antibody is a *Camelidae* VHH antibody.

Another embodiment of the present invention is a polypeptide construct as described above wherein at least one single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 1 to 7, 23 to 31, and 35 to 37.

25

Another embodiment of the present invention is a polypeptide construct as described above, wherein said single domain antibody is an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length single domain antibody.

- 30 Another embodiment of the present invention is a polypeptide construct as described above, wherein said polypeptide construct is a homologous sequence of said polypeptide construct, a functional portion thereof, of an homologous sequence of a functional portion thereof.

Another embodiment of the present invention is a nucleic acid encoding a polypeptide construct as described above.

5 Another embodiment of the present invention is a composition comprising a polypeptide construct as described above and at least one thrombolytic agent, for simultaneous, separate or sequential administration to a subject.

10 Another embodiment of the present invention is a composition as described above wherein said thrombolytic agent is any of staphylokinase, tissue plasminogen activator, streptokinase, single chain streptokinase, urokinase and acyl plasminogen streptokinase complex.

15 Another embodiment of the present invention is a polypeptide construct as described above, or a nucleic acid as described above, or a composition as described above for use in the treatment, prevention and/or alleviation of disorders relating to platelet-mediate aggregation or dysfunction thereof.

20 Another embodiment of the present invention is a use of a polypeptide construct as described above, or a nucleic acid as described above, or a composition as described above for the preparation of a medicament for the treatment, prevention and/or alleviation of disorders relating to platelet-mediate aggregation or dysfunction thereof.

25 Another embodiment of the present invention is a polypeptide construct, nucleic acid or composition as described above or a use of a polypeptide construct, nucleic acid or composition as described above wherein said disorders are any arising from arising from transient cerebral ischemic attack, unstable or stable angina, angina pectoris, cerebral infarction, myocardial infarction, peripheral arterial occlusive disease, restenosis, coronary by-pass graft, or coronary artery valve replacement and coronary interventions such angioplasty, stenting, carotid endarterectomy or atherectomy.

30 Another embodiment of the present invention is a polypeptide construct, nucleic acid or composition as described above or a use of a polypeptide construct, nucleic acid or composition as described above wherein said disorders are any of the formation of a non-occlusive thrombus, the formation of an occlusive thrombus, arterial thrombus formation,

acute coronary occlusion, restenosis, restenosis after PCTA or stenting, thrombus formation in stenosed arteries, hyperplasia after angioplasty, atherectomy or arterial stenting, occlusive syndrome in a vascular system or lack of patency of diseased arteries.

- 5 Another embodiment of the present invention is a polypeptide construct, nucleic acid or composition as described above or a use of a polypeptide construct, nucleic acid or composition as described above wherein said disorder is plaque or thrombus formation in high shear environments.
- 10 Another embodiment of the present invention is a polypeptide construct, nucleic acid or composition as described above or a use of a polypeptide construct as described above wherein said polypeptide construct is administered intravenously, subcutaneously, orally, sublingually, topically, nasally, vaginally, rectally or by inhalation.
- 15 Another embodiment of the present invention is a composition comprising a polypeptide construct as described above or a nucleic acid encoding said polypeptide construct, or a composition as described above and a pharmaceutically acceptable vehicle.

- Another embodiment of the present invention is a method of producing a polypeptide as described above, comprising
- 20 (a) culturing host cells comprising nucleic acid capable of encoding a polypeptide as described above under conditions allowing the expression of the polypeptide, and,
(b) recovering the produced polypeptide from the culture.

- 25 Another embodiment of the present invention is a method as described above, wherein said host cells are bacterial or yeast.

- Another embodiment of the present invention is a method for treating invasive medical devices to prevent platelet-mediate aggregation around the site of invasion comprising the
- 30 step of coating said device with a polypeptide construct as described above.

Another embodiment of the present invention is an invasive medical device for circumventing platelet-mediated aggregation around the site of invasion, wherein said device is coated with a polypeptide construct as described above.

- 5 Another embodiment of the present invention is a method of identifying an agent that modulates platelet-mediated aggregation comprising
- (a) contacting a polypeptide construct as described above with a polypeptide corresponding to its target, or a fragment thereof, in the presence and absence of a candidate modulator under conditions permitting binding between said polypeptides, and
- 10 (b) measuring the binding between the polypeptides of step (a), wherein a decrease in binding in the presence of said candidate modulator, relative to the binding in the absence of said candidate modulator identified said candidate modulator as an agent that modulate platelet-mediated aggregation.
- 15 Another embodiment of the present invention is a kit for screening for agents that modulate platelet-mediated aggregation according to the method as described above.

Another embodiment of the present invention is an unknown agent that modulates platelet-mediated aggregation identified according to the method as described above.

20

- Another embodiment of the present invention is a method of diagnosing a disease or disorder characterised by dysfunction of platelet-mediated aggregation comprising the steps of:
- (a) contacting a sample with a polypeptide construct as described above, and
- (b) detecting binding of said polypeptide construct to said sample, and
- 25 (c) comparing the binding detected in step (b) with a standard, wherein a difference in binding relative to said sample is diagnostic of a disease or disorder characterised by dysfunction of platelet-mediated aggregation.

- Another embodiment of the present invention is a kit for screening for diagnosing a disease or disorder characterised by dysfunction of platelet-mediated aggregation according to the method as described above.
- 30

Another embodiment of the present invention is a kit as described above comprising a polypeptide construct as described above.

DETAILED DESCRIPTION

- 5 The present invention relates to a polypeptide construct comprising one or more single domain antibodies each directed against a target and the finding that the construct has a modulating effect on platelet-mediated aggregation.

Targets

- 10 According to the invention, a target is any of vWF, vWF A1 domain, vWF A3 domain, gplb or collagen. Said targets are mammalian, and are derived from species such as rabbits, goats, mice, rats, cows, calves, camels, llamas, monkeys, donkeys, guinea pigs, chickens, sheep, dogs, cats, horses, and preferably humans. The sequence of human vWF is provided in Table 30, SEQ ID NO: 48.

15

A target is also a fragment of vWF, vWF A1 domain, vWF A3 domain, gplb or collagen, capable of eliciting an immune response. A target is also a fragment of vWF, vWF A1 domain, vWF A3 domain, gplb or collagen, capable of binding to a single domain antibody raised against the 'parent' full length target.

20

A fragment as used herein refers to less than 100% of the sequence (e.g., 99%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% etc.), but comprising 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids. A fragment is of sufficient length such that the interaction of interest is maintained with affinity of 1×10^{-8} M or better.

25

- A fragment as used herein also refers to optional insertions, deletions and substitutions of one or more amino acids which do not substantially alter the ability of the target to bind to a single domain antibody raised against the wild-type target. The number of amino acid insertions deletions or substitutions is preferably up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 or 70 amino acids.

30

A single domain antibody directed against a target means single domain antibody that it is capable of binding to its target with an affinity of better than 10^{-6} M.

Single domain antibodies

- 5 Single domain antibodies are antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be any of the art, or any
- 10 future single domain antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, goat, rabbit, bovine. According to one aspect of the invention, a single domain antibodies as used herein is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678 for example. For clarity reasons, this
- 15 variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a *VHH* or *nanobody* to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from antibodies raised in *Camelidae* species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides *Camelidae* may produce heavy chain antibodies naturally devoid of light chain; such
- 20 VHHs are within the scope of the invention.

- VHHs, according to the present invention, and as known to the skilled addressee are heavy chain variable domains derived from immunoglobulins naturally devoid of light chains such as those derived from *Camelidae* as described in WO9404678 (and referred to hereinafter as
- 25 VHH domains or nanobodies). VHH molecules are about 10x smaller than IgG molecules. They are single polypeptides and very stable, resisting extreme pH and temperature conditions. Moreover, they are resistant to the action of proteases which is not the case for conventional antibodies. Furthermore, *in vitro* expression of VHHs produces high yield, properly folded functional VHHs. In addition, antibodies generated in *Camelids* will recognize
- 30 epitopes other than those recognised by antibodies generated *in vitro* through the use of antibody libraries or via immunisation of mammals other than *Camelids* (WO 9749805). As such, anti-albumin VHH's may interact in a more efficient way with serum albumin which is known to be a carrier protein. As a carrier protein some of the epitopes of serum albumin

may be inaccessible by bound proteins, peptides and small chemical compounds. Since VHH's are known to bind into 'unusual' or non-conventional epitopes such as cavities (WO9749805), the affinity of such VHH's to circulating albumin may be increased.

5 Classes of VHH

The present invention further relates to a polypeptide construct, wherein a single domain antibody is a VHH directed to a target mentioned herein, wherein the VHH belongs to a class having human-like sequences. The class is characterised in that the VHHs carry an amino acid from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, methionine, serine, threonine, asparagine, or glutamine at position 45, such as, for example, L45 according to the Kabat numbering. A VHH sequence represented by SEQ ID NO: 1 and SEQ ID NO: 3 which bind to vWF, belong to this human-like class of VHH polypeptides. As such, peptides belonging to this class show a high amino acid sequence homology to human VH framework regions and said peptides might be administered to a human directly without expectation of an unwanted immune response therefrom, and without the burden of further humanisation.

Therefore, one aspect of the present invention allows for the direct administration of a polypeptide construct, one or more single domain antibodies correspond to a sequence represented by any of SEQ ID NOs: 1 and 3 to a patient in need of the same.

Another human-like class of *Camelidae* single domain antibodies represented by SEQ ID No. 16 and 18 have been described in WO 03/035694 and contain the hydrophobic FR2 residues typically found in conventional antibodies of human origin or from other species, but compensating this loss in hydrophilicity by a number of residues such as the charged arginine residue, serine or uncharged residues such as glycine at position 103 that substitutes the conserved tryptophan residue present in VH from double-chain antibodies. As such, peptides belonging to these two classes show a high amino acid sequence homology to human VH framework regions and said peptides might be administered to a human directly without expectation of an unwanted immune response therefrom, and without the burden of further humanisation.

Any of the VHHs as used by the invention may be of the traditional class or of the classes of human-like *Camelidae* antibodies. Said antibodies may be directed against whole targets or a fragment thereof. These polypeptides include the full length *Camelidae* antibodies, namely Fc and VHH domains, chimeric versions of heavy chain *Camelidae* antibodies with a human Fc domain.

The one or more single domain antibodies of the polypeptide construct which are directed against a target may be of the same sequence. Alternatively they may not all have the same sequence. It is within the scope of the invention that a polypeptide construct comprises anti-target single domain antibodies which do not all share the same sequence, but which are directed against the same target, or fragment thereof, one or more antigens thereof.

It is another aspect of the invention that the polypeptide construct comprises two or more single domain antibodies, wherein any two single domain antibodies are directed against different targets *i.e.* against any of vWF, vWF A1 domain, vWF A3 domain, gpIb and collagen.

Another aspect of the invention is a bispecific polypeptide construct comprising a single domain antibody directed against vWF A1 domain, and another single domain antibody directed against vWF A3 domain. Said bispecific polypeptide construct inhibits the interaction between vWF and collagen, and the interaction between vWF and platelets.

According to an aspect of the present invention a polypeptide construct may comprise two or more single domain antibodies which have been joined. The single domain antibodies may be identical in sequence and directed against the same target or antigen. Depending on the number of VHHs linked, a multivalent VHH may be bivalent (2 VHHs), trivalent (3 VHHs), tetravalent (4 VHHs) or have a higher valency molecules.

The present invention also relates to the finding that a polypeptide construct as disclosed herein further comprising one or more single domain antibodies each directed against a serum protein of a subject, surprisingly has significantly prolonged half-life in the circulation of said subject compared with the half-life of the anti-target single domain antibody(ies) when not part of said construct. Furthermore, the said constructs were found to exhibit the same

favourable properties of VHHs such as high stability remaining intact in mice, extreme pH resistance, high temperature stability and high target affinity.

5 Examples of such constructs are represented by SEQ ID No. 13 to 15, which comprise anti-vWF VHH and anti-mouse serum albumin VHH.

Therefore, another embodiment of the present invention is a polypeptide construct corresponding to a sequence represented by any of SEQ ID NOs: 13 to 15.

10 Other examples of such constructs are represented by SEQ ID No. 42 to 45, which comprise humanized anti-vWF VHH and anti-mouse serum albumin VHH.

Therefore, another embodiment of the present invention is a polypeptide construct corresponding to a sequence represented by any of SEQ ID NOs: 42 to 45.

15

The serum protein may be any suitable protein found in the serum of subject, or fragment thereof. In one aspect of the invention, the serum protein is serum albumin, serum immunoglobulins, thyroxine-binding protein, transferrin, or fibrinogen. Depending on the intended use such as the required half-life for effective treatment and/or
20 compartmentalisation of the target antigen, the VHH-partner can be directed to one of the above serum proteins.

Examples of single domain antibodies directed against serum albumin are the sequences represented by the sequences corresponding to any of SEQ ID NOs: 16 to 19 and 49 to 61.

25 Therefore another aspect of the invention is a polypeptide construct further comprising one or more anti-serum single domain antibody, wherein the sequence of a anti-serum single domain antibody corresponds to any represented by SEQ ID NOs: 16 to 19 and 49 to 61.

Such constructs are able to circulate in the subject's serum for several days, reducing the
30 frequency of treatment, the inconvenience to the subject and resulting in a decreased cost of treatment. Furthermore, it is an aspect of the invention that the half-life of the polypeptide constructs disclosed herein may be controlled by the number of anti-serum protein single domain antibodies present in the construct. A controllable half-life is desirable in several

circumstances, for example, in the application of a timed dose of a therapeutic polypeptide construct.

Another embodiment of the present invention is a polypeptide construct as mentioned herein,
5 further comprising a thrombolytic agent.

Said thrombolytic agent may be non-covalently or covalently attached to a single domain antibody *via* covalent or non-covalent means. Such covalent means are described below. Non-covalent means include *via* a protein interaction such as biotin/streptavidin, or *via* an
10 immunoconjugate.

Alternatively, the thrombolytic agent may be administered simultaneous, separate or sequential in respect of a polypeptide construct of the invention.

15 Another aspect of the invention is a composition comprising at least one polypeptide construct as disclosed herein and at least one thrombolytic agent, for simultaneous, separate or sequential administration to a subject.

One aspect of the invention is a method for treating autoimmune disease comprising
20 administering to an individual an effective amount of at least one polypeptide construct of the invention and at least one thrombolytic agent, simultaneously, separately or sequentially.

Another aspect of the invention is a kit containing at least one polypeptide construct of the invention and at least one thrombolytic agent for simultaneous, separate or sequential
25 administration to a subject. It is an aspect of the invention that the kit may be used according to the invention. It is an aspect of the invention that the kit may be used to treat the diseases as cited herein.

By simultaneous administration means the polypeptide and thrombolytic agent are
30 administered to a subject at the same time. For example, as a mixture or a composition comprising said components. Examples include, but are not limited to a solution administered intravenously, a tablet, liquid, topical cream, etc., wherein each preparation comprises the components of interest.

By separate administration means polypeptide and thrombolytic agent are administered to a subject at the same time or substantially the same time. The components are present in the kit as separate, unmixed preparations. For example, the polypeptide and thrombolytic agent may be present in the kit as individual tablets. The tablets may be administered to the subject
5 by swallowing both tablets at the same time, or one tablet directly following the other.

By sequential administration means the polypeptide and thrombolytic agent are administered to a subject sequentially. The polypeptide and thrombolytic agent are present in the kit as separate, unmixed preparations. There is a time interval between doses. For example, one
10 component might be administered up to 336, 312, 288, 264, 240, 216, 192, 168, 144, 120, 96, 72, 48, 24, 20, 16, 12, 8, 4, 2, 1, or 0.5 hours after the other component.

In sequential administration, one component may be administered once, or any number of times and in various doses before and/or after administration of another component.
15 Sequential administration may be combined with simultaneous or sequential administration.

The medical uses of the polypeptide construct described below, also apply to the composition comprising a polypeptide construct as disclosed herein and at least one polypeptide thrombolytic agent, for simultaneous, separate or sequential administration to a subject as
20 disclosed here above.

Thrombolytic agents according to the invention may include, for example, staphylokinase, tissue plasminogen activator, streptokinase, single chain streptokinase, urokinase and acyl plasminogen streptokinase complex.
25

The single domain antibodies may be joined to form any of the polypeptide constructs disclosed herein comprising more than one single domain antibody using methods known in the art or any future method. For example, they may be fused by chemical cross-linking by reacting amino acid residues with an organic derivatisation agent such as described by
30 Blattler *et al*, Biochemistry 24,1517-1524; EP294703. Alternatively, the single domain antibody may be fused genetically at the DNA level *i.e.* a polynucleotide construct formed which encodes the complete polypeptide construct comprising one or more anti-target single domain antibodies and one or more anti-serum protein single domain antibodies. A method

for producing bivalent or multivalent VHH polypeptide constructs is disclosed in PCT patent application WO 96/34103. One way of joining multiple single domain antibodies is via the genetic route by linking single domain antibody coding sequences either directly or via a peptide linker. For example, the C-terminal end of the first single domain antibody may be
5 linked to the N-terminal end of the next single domain antibody. This linking mode can be extended in order to link additional single domain antibodies for the construction and production of tri-, tetra-, etc. functional constructs.

10 The polypeptide constructs disclosed herein may be made by the skilled artisan according to methods known in the art or any future method. For example, VHHs may be obtained using methods known in the art such as by immunising a camel and obtaining hybridoma's therefrom, or by cloning a library of single domain antibodies using molecular biology techniques known in the art and subsequent selection by using phage display.

15 One aspect of the present invention relates to the finding that polypeptides represented by SEQ ID NOs: 1 to 7 as in Table 30 derived from *Camelidae* VHHs, bind to vWF and inhibit its interaction with collagen.

20 Therefore, one embodiment of the present invention is a polypeptide construct wherein at least one single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 1 to 7.

25 Another embodiment of the present invention is a polypeptide construct corresponding to a sequence represented by any of SEQ ID NOs: 8 to 12. Said sequences correspond to monospecific polypeptide constructs (such as in SEQ ID No. 8 and 11) or heterospecific polypeptide constructs comprising VHHs of different sequences (such as in SEQ ID No. 9, 10 and 12), both directed against vWF.

30 Another embodiment of the present invention a polypeptide construct comprising one or more single domain antibodies directed against vWF.

Platelet aggregation is a very complex phenomenon and in an *in vivo* situation, the interaction of vWF with collagen only takes place at high shear as observed in small arteries. To assess platelet aggregation under high shear, the inventors performed perfusion experiments.

Example 16 represents shear data obtained with the specific vWF-A3 binders SEQ ID No. 1 to 12. This experiment is representative for the interactions that take place upon damage of the vessel wall in a small artery (for example during angioplasty).

- 5 Surprisingly, monovalent VHH's perform very well in a platelet aggregation experiment under high shear: 50% inhibition of platelet aggregation was obtained at a concentration between 0.08 and 0.3 $\mu\text{g/ml}$. In comparison, the IgG vWF-specific antibody inhibiting the interaction with collagen, 82D6A3, inhibits 50% of platelet aggregation at approximately a twenty-fold higher concentration (Vanhoorelbeke K. *et al*, *Journal of Biological Chemistry*, 2003, 278: 37815-37821). These results were unexpected given that the IC50 values for the monovalent VHH's are up to 7 times fold worse in ELISA than the IC50 value of the IgG of 82D6A3.

15 This clearly proves that the large size of said antibodies is not suited to interaction with macromolecules which are starting, or are in the process of aggregating, such as those involved in platelet-mediated aggregation. vWF forms multimers of up to 60 monomers (final multimers of up to 20 million dalton in size). Indeed, it has been shown that not all A3 domains are accessible to 82D6A3 (Dongmei WU, *Blood*, 2002, 99, 3623 to 3628). Furthermore the large size of conventional antibodies, would restrict tissue penetration, for example, during platelet-mediated aggregation at the site of a damaged vessel wall.

20 Nanobodies have a unique structure that consists of a single variable domain. VHH molecules derived from *Camelidae* antibodies are among the smallest intact antigen-binding domains known (approximately 15 kDa, or 10 times smaller than a conventional IgG) and hence are well suited towards delivery to dense tissues and for accessing the limited space between macromolecules participating in or starting the process of platelet mediated aggregation.

30 To our knowledge, this is the first time that experiments show, that the small size of a nanobody is advantages over a large intact antibody for inhibition of interactions between such large macromolecules.

Despite the small size of nanobodies, and thus advantages for penetration, it is still surprising that such a small molecule can inhibit interactions between large polymers such as vWF (up to 60 monomers) and collagen and with such a high efficiency. It has been described that

only the large multimeric forms of vWF are hemostatically active (Furlan, M., 1996, *Ann. Hematol.* 72:341-348). Binding of multimeric vWF to collagen occurs with ~100-fold higher affinity than binding of monomeric vWF fragments.

- 5 The results from the high shear experiments indicate that a lower dose may be administered to patients. Therefore, fewer side effects are expected (such as immunogenicity or bleeding problems).

10 The present invention also relates to the finding that the polypeptides corresponding to a sequence represented by any of SEQ ID NOs 23 to 31 from single domain llama antibodies, bind to the A1 domain of vWF.

Therefore, another embodiment of the present invention is a polypeptide construct comprising one or more single domain antibodies, each single domain antibody corresponding to a
15 sequence represented by any of SEQ ID NOs: 23 to 31.

Another embodiment of the present invention a polypeptide construct corresponding to a sequence represented by any of SEQ ID NOs: 32 to 34. Said sequences correspond to bivalent polypeptide constructs comprising VHHs of the same sequences, both directed
20 against vWF A1 domain.

The inventors have performed perfusion experiment a flow chamber, to study the effect of polypeptide constructs comprising sequences represented by SEQ ID NOs: 23 to 31 upon platelet aggregation under high shear. Example 25 provides shear data obtained with the
25 specific vWF-A1 binders SEQ ID No. 23 to 31

In another embodiment of the present invention, a polypeptide construct comprises one or more single domain antibodies directed to the same target, and further comprises one or more single domain antibodies directed to the same target but to a different epitope in the
30 same domain.

For example, the sequences represented by SEQ ID NOs: 9, 10 and 12 are heterospecific polypeptide constructs comprising VHHs directed to different epitopes in the A3 domain of

vWF. Therefore, another embodiment of the present invention a polypeptide construct corresponding to a sequence represented by any of SEQ ID NOs: 9, 10 and 12.

Another embodiment of the present invention is a polypeptide construct wherein the number
5 of single domain antibodies directed to the same target is two or more.

The sequences represented by SEQ ID NOs: 8 and 11 are polypeptide constructs comprising VHHs directed to the same epitopes in the A3 domain of vWF, wherein the both VHHs have identical sequences. Therefore, another embodiment of the present invention is a polypeptide
10 construct corresponding to a sequence represented by any of SEQ ID NOs: 8 and 11.

In another embodiment of the present invention, a polypeptide construct comprises one or more single domain antibodies directed to one domain of the same target, and one or more single domain antibodies directed to the same target but to another domain of the same
15 target. Examples of different domains might be the A1 and A3 domains of vWF

In another example, the sequences represented by SEQ ID NOs: 20, 21 and 22 are heterospecific polypeptide constructs comprising VHHs directed to epitopes on different domains of vWF *i.e.* A1 and A3 of vWF. Therefore, another embodiment of the present
20 invention is a polypeptide construct corresponding to a sequence represented by any of SEQ ID NOs: 20, 21 and 22.

Such polypeptide constructs may have superior anti-thrombotic effects compared to the monomeric VHH's. Perfusion experiment were performed in a flow chamber, to study platelet
25 aggregation under high shear to study the effects of these polypeptide constructs. Example 30 represents shear data obtained with the heterospecific polypeptide construct comprising anti vWF-A1 VHH and anti-vWF-A3 VHH.

The present invention also relates to the finding that the polypeptides represented by SEQ ID
30 NOs 35 to 37 from single domain llama antibodies, bind to collagen type I and/or type III.

Therefore, another embodiment of the present invention is a polypeptide construct, wherein at least one single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 35 to 37.

- 5 In another embodiment of the present invention, a polypeptide construct comprises one or more single domain antibodies directed to the collagen I and/or type III, and one or more single domain antibodies directed to the same target but to a different epitope in the same domain. The sequences represented by 3P1-31_3P2-31 and 3L-41_3P2-31 are heterospecific polypeptide constructs comprising VHHs directed to different epitopes in collagen type I. Therefore, another embodiment of the present invention a polypeptide
10 construct corresponding to a sequence represented by any of SEQ ID NOs: 46 and 47.

Another aspect of the invention is a polypeptide construct comprising one or more single domain antibodies directed to the platelet glycoprotein Ib.

15

- A murine anti-human vWF monoclonal antibody, AJvW-2 (IgG), was developed that inhibited the interaction between platelet glycoprotein Ib (gplb) and von Willebrand factor (vWF) during the ristocetin- and botrocetin- induced aggregation of human platelets (PCT application number WO 00/10601). AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without
20 bleeding time prolongation in dogs (Kageyama S et al, Thromb Res., 2001 Mar 1;101(5):395-404) and prevents thrombus deposition and neointima formation after balloon injury in guinea pigs (Kageyama S, et al, Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2303-8).

- Antibody 6B4 is a monoclonal antibody (MoAb) raised against purified human gplb (PCT application number WO 01/10911 A2). When injected into baboons, intact IgG and its F(ab')₂ fragments caused almost immediate thrombocytopenia, due to the bivalency of F(ab')₂ which mediates platelet crosslinking, or Fc:Fc receptor interactions which mediate activation of platelet aggregation (Cauwenberghs N. *et al*, Arteriosclerosis, Thrombosis and Vascular biology, 2000, 20: 1347 and see, for example, Cadroy Y et al, Blood, 1994, 83: 3218-3224,
25 Becker BH et al, blood, 1989, 74: 690-694, Ravanat C. et al, Thromb. Haemost. 1999, 82 : 528a abstract). Platelet deposition onto collagen-rich bovine pericardium was inhibited when Fab fragments were injected into the baboons before a thrombus was generated. However,
30

when the Fab fragments were injected after a thrombus was allowed to form, no inhibition of further thrombosis was observed.

It was shown that the affinity of the Fab fragment for the gplb receptor on the platelet dropped by a factor of 10 as compared to the intact IgG or F(ab')₂ (K_D= 49.2 nM, 4.7 nM and 6.4 nM respectively). Also the IC₅₀ value for ristocetin-induced platelet aggregation was up to 10-fold worse for Fab as compared to IgG or F(ab')₂ (IC₅₀ of 40 nM, 4.5 nM and 7.7 nM respectively).

It might be expected that the undesirable thrombocytopenia caused by Fc:Fc receptor mediated activation of platelet aggregation and/or F(ab')₂-mediated crosslinking of platelets which has been observed when using intact IgG or F(ab')₂ therapeutically *in vivo*, will be avoided by the use of VHH, since VHH contains no Fc and it is not bivalent. No loss of affinity and activity will be obtained as observed with the Fab fragment of 6B4 as nanobodies are already single domain molecules.

Humanising antibodies

The discovery of naturally occurring single domain antibodies in llama, dromedary and camel revealed a new class of therapeutic molecules which combine the advantages of monoclonal antibodies for example specificity, low toxicity with the advantages of small molecules for example tissue penetration and stability. Unfortunately, the development of appropriate therapeutic products based on these proteins has the drawback of being *Camelidae* derived, and thus not human. Non-human proteins contain amino acid residues that can be immunogenic when injected into a human patient. Although studies have shown that *Camelidae*-derived VHH are not immunogenic when injected in mice, replacing *Camelidae* residues by human residues is preferable. These humanized polypeptides should be substantially non-immunogenic in humans, but retain the affinity and activity of the wild type polypeptide.

By humanised is meant mutated so that immunogenicity upon administration in human patients is minor or nonexistent. Humanising a polypeptide, according to the present invention, comprises a step of replacing one or more of the *Camelidae* amino acids by their human counterpart as found in the human consensus sequence, without that polypeptide

losing its typical character, *i.e.* the humanisation does not significantly affect the antigen binding capacity of the resulting polypeptide.

5 The inventors have determined the amino acid residues of the antibody variable domain (VHH) which may be modified without diminishing the native affinity of the domain for antigen and while reducing its immunogenicity with respect to a heterologous species; the use of VHHs having modifications at the identified residues which are useful for administration to heterologous species; and to the VHH so modified. More specifically, the invention relates to the preparation of modified VHHs, which are modified for administration to humans, the
10 resulting VHH themselves, and the use of such "humanized" VHHs in the treatment of diseases in humans.

The inventor have also found that humanization of VHH polypeptides requires the introduction and mutagenesis of only a limited number of amino acids in a single polypeptide chain without dramatic loss of binding and/or inhibition activity. This is in contrast to
15 humanization of scFv, Fab, (Fab)2 and IgG, which requires the introduction of amino acid changes in two chains, the light and the heavy chain and the preservation of the assembly of both chains.

A humanisation technique may be performed by a method comprising the replacement of any
20 of the following residues either alone or in combination: FR1 positions 1, 5, 28 and 30, the hallmark amino acid at position 37, 44, 45 and 47 in FR2, FR3 residues 74, 75, 76, 83, 84, 93 and 94 and positions 103, 104, 108 and 111 in FR4; numbering according to the Kabat numbering. Examples of such humanized sequences are given in Table 30, SEQ ID No. 2, 38 to 41.

25 Polypeptides represented in example 63 and 64 have a high degree of homology to human germline VH DP-47. Further humanization required the introduction and mutagenesis of a limited amount of amino acids in a single polypeptide chain. This is in contrast to humanization of scFv, Fab, (Fab)2 and IgG, which requires the introduction of amino acid
30 changes in two chains, the light and the heavy chain and the preservation of the assembly of both chains.

The polypeptides contain human-like residues in FR2. Humanization required mutagenesis of residues in FR1 at position 1 and 5 which were introduced by the primer used for repertoire cloning and do not occur naturally in the llama sequence. Mutagenesis of those residues did not result in loss of binding and/or inhibition activity. Humanization of FR1 also required mutagenesis of position 28 and 30. Mutagenesis of those residues also did not result in loss of binding and/or inhibition activity.

Humanization also required mutagenesis of residues in FR3 at position 74, 75, 76, 83, 84, 93, 94. Mutagenesis of those residues did not result in loss of binding and/or inhibition activity.

Humanization also required mutagenesis of residues in FR4 at position 104, 108 and 111. Mutagenesis of Q108L resulted in lower production level in *Escherichia coli*. Position 108 is solvent exposed in camelid VHH, while in human antibodies this position is buried at the VH-VL interface (Spinelli, 1996; Nieba, 1997). In isolated VHs position 108 is solvent exposed. The introduction of a non-polar hydrophobic Leu instead of polar uncharged Gln can have a drastic effect on the intrinsic foldability/stability of the molecule.

One embodiment of the present invention is a method for humanizing a VHH comprising the steps of:

(a) replacing of any of the following residues either alone or in combination:

FR1 positions 1, 5, 28 and 30,

the hallmark amino acid at position 37, 44, 45 and 47 in FR2,

FR3 residues 74, 75, 76, 83, 84, 93 and 94 ,

and positions 103, 104, 108 and 111 in FR4 ;

numbering according to the Kabat numbering.

Examples of such humanized sequences are given in Table 30, SEQ ID No. 2, 38 to 41.

The use of antibodies derived from sources such as mouse, sheep, goat, rabbit etc., and humanised derivatives thereof as a treatment for conditions which require a modulation of platelet-associated aggregation, is problematic for several reasons. Traditional antibodies are not stable at room temperature, and have to be refrigerated for preparation and storage, requiring necessary refrigerated laboratory equipment, storage and transport, which

contribute towards time and expense. Refrigeration is sometimes not feasible in developing countries. The yields of expression of said Fab molecules are very low and the method of production is very labor intensive. Furthermore, the manufacture or small-scale production of said antibodies is expensive because the mammalian cellular systems necessary for the
5 expression of intact and active antibodies require high levels of support in terms of time and equipment, and yields are very low. Furthermore, traditional antibodies have a binding activity which depends upon pH, and hence are unsuitable for use in environments outside the usual physiological pH range such as, for example, in treating gastric bleeding, gastric surgery. Furthermore, traditional antibodies are unstable at low or high pH and hence are not suitable
10 for oral administration. However, it has been demonstrated that camelid antibodies resist harsh conditions, such as extreme pH, denaturing reagents and high temperatures (Ewert S et al, Biochemistry 2002 Mar 19;41(11):3628-36), so making them suitable for delivery by oral administration. Furthermore, traditional antibodies have a binding activity which depends upon temperature, and hence are unsuitable for use in assays or kits performed at
15 temperatures outside biologically active-temperature ranges (e.g. $37 \pm 20^\circ\text{C}$).

The polypeptide constructs represented by SEQ ID NOs: 1 to 47 and their derivatives not only possess the advantageous characteristics of conventional antibodies, such as low toxicity and high selectivity, but they also exhibit additional properties. They are more soluble,
20 meaning they may be stored and/or administered in higher concentrations compared with conventional antibodies. They are stable at room temperature meaning they may be prepared, stored and/or transported without the use of refrigeration equipment, conveying a cost, time and environmental savings (described in example 61). Other advantageous characteristics as compared to conventional antibodies include short half-life in the circulation
25 which may be modulated according to the invention by, for example, albumin-coupling, a bispecific nanobody with one specificity against albumin and the other against the target, Fc coupling, VHH coupling (bivalent VHHs) or by pegylation (described in example 41 until 54). A short and controllable half-life is desirable for surgical procedures, for example, which require an inhibition of platelet-mediated aggregation for a limited time period. Also, when
30 bleeding problems occur or other complications, dosage can be lowered immediately. The polypeptides of the present invention also retain binding activity at a pH and temperature outside those of usual physiological ranges, which means they may be useful in situations of extreme pH and temperature which require a modulation of platelet-mediated aggregation,

such as in gastric surgery, control of gastric bleeding, assays performed at room temperature etc. The polypeptides of the present invention also exhibit a prolonged stability at extremes of pH, meaning they would be suitable for delivery by oral administration. The polypeptides of the present invention may be cost-effectively produced through fermentation in convenient recombinant host organisms such as *Escherichia coli* and yeast; unlike conventional antibodies which also require expensive mammalian cell culture facilities, achievable levels of expression are high. Examples of yields of the polypeptides of the present invention are 1 to 10 mg/ml (*E. coli*) and up to 1g/l (yeast). The polypeptides of the present invention also exhibit high binding affinity for a broad range of different antigen types; and ability to bind to epitopes not recognised by conventional antibodies; for example they display long CDR-based loop structures with the potential to penetrate into cavities and exhibit enzyme function inhibition. Furthermore, since binding often occurs through the CDR3 loop only, it is envisaged that peptides derived from CDR3 could be used therapeutically (Desmyter *et al.*, *J Biol Chem*, 2001, 276: 26285-90). The preparation of such peptide is described in Example 65. The polypeptides of the invention are also able to retain full binding capacity as fusion protein with an enzyme or toxin. Furthermore, it might be expected that the undesirable thrombocytopenia caused by Fc:Fc receptor mediated activation of platelet aggregation and/or F(ab')(2)-mediated crosslinking of platelets which has been observed when using intact IgG or F(ab')(2) therapeutically *in vivo* (see Cauwenberghs N. *et al*, *Arteriosclerosis, Thrombosis and Vascular biology*, 2000, 20: 1347), will be avoided in the use of VHH, since VHH contains no Fc and it is not bivalent. Thus the polypeptides represented by SEQ ID NOs: 1 to 47, homologues or functional portions thereof provide a considerable cost and time saving in the treatment and diagnosis of conditions related to platelet-mediated aggregation, and the patient in need of said polypeptides would encounter fewer of the problems associated with conventional agents.

Platelet-mediated aggregation is the process wherein vWF-bound collagen adheres to platelets and/or platelet receptors (examples of both are gpla/IIa, gplb, or collagen), ultimately resulting in platelet activation. Platelet activation leads to fibrinogen binding, and finally to platelet aggregation. It is within the scope of the present invention to provide polypeptides which modulate the processes which comprise platelet-mediated aggregation such as vWF-collagen binding, vWF-platelet receptor adhesion, collagen-platelet receptor adhesion, platelet activation, fibrinogen binding and/or platelet aggregation. Said polypeptides are

derived from *Camelidae* antibodies directed towards vWF, vWF A1 or A3 domains, gpIb or collagen, and share the same advantages as the polypeptides represented by SEQ ID NOs: 1 to 47, as described above.

- 5 According to an aspect of the invention a polypeptide construct may be a homologous sequence of a full-length polypeptide construct. According to another aspect of the invention, a polypeptide construct may be a functional portion of a full-length polypeptide construct. According to another aspect of the invention, a polypeptide construct may be a homologous sequence of a full length polypeptide construct. According to another aspect of the invention,
- 10 a polypeptide construct may be a functional portion of a homologous sequence of a full length polypeptide construct. According to an aspect of the invention a polypeptide construct may comprise a sequence of a polypeptide construct.

- According to an aspect of the invention a single domain antibody used to form a polypeptide
- 15 construct may be a complete single domain antibody (e.g. a VHH) or a homologous sequence thereof. According to another aspect of the invention, a single domain antibody used to form the polypeptide construct may be a functional portion of a complete single domain antibody. According to another aspect of the invention, a single domain antibody used to form the polypeptide construct may be a homologous sequence of a complete single
- 20 domain antibody. According to another aspect of the invention, a single domain antibody used to form the polypeptide construct may be a functional portion of a homologous sequence of a complete single domain antibody.

- Another aspect of the present invention are the single domain antibodies corresponding to
- 25 SEQ ID NOs: 1 to 47, a homologous sequence thereof, and/or a functional portion thereof.

- According to another aspect of the invention a polypeptide construct may be an homologous sequence of the parent sequence. According to another aspect of the invention, a polypeptide construct may be a functional portion parent sequence. According to another aspect of the
- 30 invention, a polypeptide construct may be a functional portion of a homologous sequence of the parent sequence.

As used herein, an homologous sequence may comprise additions, deletions or substitutions of one or more amino acids, which do not substantially alter the functional characteristics of the polypeptide. The number of amino acid deletions or substitutions is preferably up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 or 70 amino acids.

An homologous sequence according to the present invention includes polypeptides extended by the addition of amino acids to form human heavy chain antibody or human single domain heavy chain antibody, which do not substantially alter the functional characteristics of the unmodified polypeptide.

A homologous sequence of the present invention may include a polypeptide represented by any of SEQ ID NOs: 1 to 47, which has been humanised (as described in examples 63 and 64).

A homologous sequence of the present invention may include a sequence corresponding to the sequence of SEQ ID NOs: 1 to 47 which exists in other *Camelidae* species such as, for example, camel, llama, dromedary, alpaca, guanaco etc.

Where homologous sequence indicates sequence identity, it means a sequence which presents a high sequence identity (more than 70%, 75%, 80%, 85%, 90%, 95% or 98% sequence identity) with the parent sequence, and is preferably characterised by similar properties of the parent sequence, namely affinity, said identity calculated using known methods.

Alternatively, an homologous sequence may also be any amino acid sequence resulting from allowed substitutions at any number of positions of the parent sequence according to the formula below:

Ser substituted by Ser, Thr, Gly, and Asn;
 Arg substituted by one of Arg, His, Gln, Lys, and Glu;
 Leu substituted by one of Leu, Ile, Phe, Tyr, Met, and Val;
 Pro substituted by one of Pro, Gly, Ala, and Thr;

Thr substituted by one of Thr, Pro, Ser, Ala, Gly, His, and Gln;

Ala substituted by one of Ala, Gly, Thr, and Pro;

Val substituted by one of Val, Met, Tyr, Phe, Ile, and Leu;

Gly substituted by one of Gly, Ala, Thr, Pro, and Ser;

5 Ile substituted by one of Ile, Met, Tyr, Phe, Val, and Leu;

Phe substituted by one of Phe, Trp, Met, Tyr, Ile, Val, and Leu;

Tyr substituted by one of Tyr, Trp, Met, Phe, Ile, Val, and Leu;

His substituted by one of His, Glu, Lys, Gln, Thr, and Arg;

Gln substituted by one of Gln, Glu, Lys, Asn, His, Thr, and Arg;

10 Asn substituted by one of Asn, Glu, Asp, Gln, and Ser;

Lys substituted by one of Lys, Glu, Gln, His, and Arg;

Asp substituted by one of Asp, Glu, and Asn;

Glu substituted by one of Glu, Asp, Lys, Asn, Gln, His, and Arg;

Met substituted by one of Met, Phe, Ile, Val, Leu, and Tyr.

15

A homologous according to the present invention may refer to nucleotide sequences of more than 50, 100, 200, 300, 400, 500, 600, 800 or 1000 nucleotides able to hybridize to the reverse-complement of the nucleotide sequence capable of encoding a polypeptide under stringent hybridisation conditions (such as the ones described by SAMBROOK *et al.*,

20 Molecular Cloning, Laboratory Manuel, Cold Spring, Harbor Laboratory press, New York).

As used herein, a functional portion refers to a single domain antibody of sufficient length such that the interaction of interest is maintained with affinity of 1×10^{-6} M or better.

25 Alternatively a functional portion of a single domain antibody of the invention comprises a partial deletion of the complete amino acid sequence and still maintains the binding site(s) and protein domain(s) necessary for the binding of and interaction with the target.

30 Alternatively a functional portion of any of SEQ ID NO: 1 to 7 is a polypeptide which comprises a partial deletion of the complete amino acid sequence and which still maintains the binding site(s) and protein domain(s) necessary for the inhibition of binding of vWF to collagen.

Alternatively a functional portion of any of SEQ ID NOs: 23 to 31 is a polypeptide which comprises a partial deletion of the complete amino acid sequence and which still maintains the binding site(s) and protein domain(s) necessary for the binding of and interaction with the A1 domain of vWF.

5

Alternatively a functional portion of any of SEQ ID NOs: 35 to 37 is a polypeptide which comprises a partial deletion of the complete amino acid sequence and which still maintains the binding site(s) and protein domain(s) necessary for the binding of and interaction with collagen.

10

Alternatively a functional portion comprises a partial deletion of the complete amino acid sequence of a polypeptide and which still maintains the binding site(s) and protein domain(s) necessary for the binding of and interaction with the antigen against which it was raised. It includes, but is not limited to VHH domains.

15

As used herein, a functional portion as it refers to a polypeptide sequence refers to less than 100% of the sequence (e.g., 99%, 90%, 80%, 70%, 60% 50% etc.), but comprising 5 or more amino acids.

20

A portion as it refers to a nucleotide sequence encoding a polypeptide sequence refers to less than 100% of the sequence (e.g., 99%, 90%, 80%, 70%, 60% 50% etc.), but comprising 15 or more nucleotides.

25

An aspect of the present invention is the administration of a polypeptide construct according to the invention can avoid the need for injection. Conventional antibody-based therapeutics have significant potential as drugs because they have exquisite specificity to their target and a low inherent toxicity, however, they have one important drawback: they are relatively unstable, and are sensitive to breakdown by proteases. This means that conventional antibody drugs cannot be administered orally, sublingually, topically, nasally, vaginally, rectally or by inhalation because they are not resistant to the low pH at these sites, the action of proteases at these sites and in the blood and/or because of their large size. They have to be administered by injection (intravenously, subcutaneously, etc.) to overcome some of these problems. Administration by injection requires specialist training in order to use a hypodermic

30

syringe or needle correctly and safely. It further requires sterile equipment, a liquid formulation of the therapeutic polypeptide, vial packing of said polypeptide in a sterile and stable form and, of the subject, a suitable site for entry of the needle. Furthermore, subjects commonly experience physical and psychological stress prior to and upon receiving an
5 injection.

An aspect of the present invention overcomes these problems of the prior art, by providing the polypeptides constructs of the present invention. Said constructs are sufficiently small, resistant and stable to be delivered orally, sublingually, topically, nasally, vaginally, rectally or
10 by inhalation substantial without loss of activity. The polypeptides constructs of the present invention avoid the need for injections, are not only cost/time savings, but are also more convenient and more comfortable for the subject.

One embodiment of the present invention is a polypeptide construct as disclosed herein for
15 use in treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation which is able pass through the gastric environment without the substance being inactivated.

As known by persons skilled in the art, once in possession of said polypeptide construct,
20 formulation technology may be applied to release a maximum amount of polypeptide in the right location (in the stomach, in the colon, etc.). This method of delivery is important for treating, prevent and/or alleviate the symptoms of disorders whose targets are located in the gut system.

25 An aspect of the invention is a method for treating, preventing and/or alleviating the symptoms of a disorder susceptible to modulation by a substance that controls platelet mediated aggregation which is able pass through the gastric environment without being inactivated, by orally administering to a subject a polypeptide construct as disclosed herein.

30 Another embodiment of the present invention is a use of a polypeptide construct as disclosed herein for the preparation of a medicament for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet

mediated aggregation which is able pass through the gastric environment without being inactivated.

5 An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the gut system without said substance being inactivated, by orally administering to a subject a polypeptide construct as disclosed herein.

10 An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the bloodstream of a subject without the substance being inactivated, by orally administering to a subject a polypeptide construct as disclosed herein.

15 Another embodiment of the present invention is a polypeptide construct as disclosed herein for use in treating, preventing and/or alleviating the symptoms or disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the vaginal and/or rectal tract.

20 In a non-limiting example, a formulation according to the invention comprises a polypeptide construct as disclosed herein, in the form of a gel, cream, suppository, film, or in the form of a sponge or as a vaginal ring that slowly releases the active ingredient over time (such formulations are described in EP 707473, EP 684814, US 5629001).

25 An aspect of the invention is a method for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the vaginal and/or rectal tract, by vaginally and/or rectally administering to a subject a polypeptide construct as disclosed herein.

30 Another embodiment of the present invention is a use of a polypeptide construct as disclosed herein for the preparation of a medicament for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the vaginal and/or rectal tract.

An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the vaginal and/or rectal tract without being said substance being

inactivated, by administering to the vaginal and/or rectal tract of a subject a polypeptide construct as disclosed herein.

5 An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the bloodstream of a subject without said substance being inactivated, by administering to the vaginal and/or rectal tract of a subject a polypeptide construct as disclosed herein.

10 Another embodiment of the present invention is a polypeptide construct as disclosed herein, for use in treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the nose, upper respiratory tract and/or lung.

15 In a non-limiting example, a formulation according to the invention, comprises a polypeptide construct as disclosed herein in the form of a nasal spray (e.g. an aerosol) or inhaler. Since the polypeptide construct is small, it can reach its target much more effectively than therapeutic IgG molecules.

20 An aspect of the invention is a method for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the upper respiratory tract and lung, by administering to a subject a polypeptide construct as disclosed herein, by inhalation through the mouth or nose.

25 Another embodiment of the present invention is a use of a polypeptide construct as disclosed herein for the preparation of a medicament for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the nose, upper respiratory tract and/or lung, without said polypeptide being inactivated.

30 An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the nose, upper respiratory tract and lung without inactivation, by administering to the nose, upper respiratory tract and/or lung of a subject a polypeptide construct as disclosed herein.

An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the bloodstream of a subject without inactivation by administering to the nose, upper respiratory tract and/or lung of a subject a polypeptide construct as disclosed
5 herein.

One embodiment of the present invention is a polypeptide construct as disclosed herein for use in treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the
10 intestinal mucosa, wherein said disorder increases the permeability of the intestinal mucosa. Because of their small size, a polypeptide construct as disclosed herein can pass through the intestinal mucosa and reach the bloodstream more efficiently in subjects suffering from disorders which cause an increase in the permeability of the intestinal mucosa.

15 An aspect of the invention is a method for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the intestinal mucosa, wherein said disorder increases the permeability of the intestinal mucosa, by orally administering to a subject a polypeptide construct as disclosed herein.

20 This process can be even further enhanced by an additional aspect of the present invention - the use of active transport carriers. In this aspect of the invention, VHH is fused to a carrier that enhances the transfer through the intestinal wall into the bloodstream. In a non-limiting example, this "carrier" is a second VHH which is fused to the therapeutic VHH. Such fusion
25 constructs are made using methods known in the art. The "carrier" VHH binds specifically to a receptor on the intestinal wall which induces an active transfer through the wall.

Another embodiment of the present invention is a use of a polypeptide construct as disclosed herein for the preparation of a medicament for treating, preventing and/or alleviating the
30 symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation delivered to the intestinal mucosa, wherein said disorder increases the permeability of the intestinal mucosa.

An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the intestinal mucosa without being inactivated, by administering orally to a subject a polypeptide construct of the invention.

- 5 An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the bloodstream of a subject without being inactivated, by administering orally to a subject a polypeptide construct of the invention.

10 This process can be even further enhanced by an additional aspect of the present invention - the use of active transport carriers. In this aspect of the invention, a polypeptide construct as described herein is fused to a carrier that enhances the transfer through the intestinal wall into the bloodstream. In a non-limiting example, this "carrier" is a VHH which is fused to said polypeptide. Such fusion constructs made using methods known in the art. The "carrier" VHH binds specifically to a receptor on the intestinal wall which induces an active transfer through
15 the wall.

One embodiment of the present invention is a polypeptide construct as disclosed herein for use in treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation which is able pass
20 through the tissues beneath the tongue effectively. A formulation of said polypeptide construct as disclosed herein, for example, a tablet, spray, drop is placed under the tongue and adsorbed through the mucus membranes into the capillary network under the tongue.

25 An aspect of the invention is a method for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation which is able pass through the tissues beneath the tongue effectively, by sublingually administering to a subject a polypeptide construct as disclosed herein.

30 Another embodiment of the present invention is a use of a polypeptide construct as disclosed herein for the preparation of a medicament for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation which is able to pass through the tissues beneath the tongue.

An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the tissues beneath the tongue without being inactivated, by administering sublingually to a subject a polypeptide construct as disclosed herein.

- 5 An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the bloodstream of a subject without being inactivated, by administering orally to a subject a polypeptide construct as disclosed herein.

10 One embodiment of the present invention is a polypeptide construct as disclosed herein for use in treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation which is able pass through the skin effectively.

15 A formulation of said polypeptide construct, for example, a cream, film, spray, drop, patch, is placed on the skin and passes through.

20 An aspect of the invention is a method for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation which is able pass through the skin effectively, by topically administering to a subject a polypeptide construct as disclosed herein.

25 Another embodiment of the present invention is a use of a polypeptide construct as disclosed herein for the preparation of a medicament for treating, preventing and/or alleviating the symptoms of disorders susceptible to modulation by a substance that controls platelet mediated aggregation which is able pass through the skin effectively.

30 An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the skin without being inactivated, by administering topically to a subject a polypeptide construct as disclosed herein.

An aspect of the invention is a method for delivering a substance that controls platelet mediated aggregation to the bloodstream of a subject, by administering topically to a subject a polypeptide construct as disclosed herein.

In another embodiment of the present invention, a polypeptide construct as disclosed herein further comprises a carrier single domain antibody (e.g. VHH) which acts as an active transport carrier for transport of said polypeptide construct via the lung lumen to the blood.

5

A polypeptide construct further comprising a carrier that binds specifically to a receptor present on the mucosal surface (bronchial epithelial cells) resulting in the active transport of the polypeptide from the lung lumen to the blood. The carrier single domain antibody may be fused to the polypeptide construct. Such fusion constructs made using methods known in the art and are describe herein. The "carrier" single domain antibody binds specifically to a receptor on the mucosal surface which induces an active transfer through the surface.

10

Another aspect of the present invention is a method to determine which single domain antibodies (e.g. VHHs) are actively transported into the bloodstream upon nasal administration. Similarly, a naïve or immune VHH phage library can be administered nasally, and after different time points after administration, blood or organs can be isolated to rescue phages that have been actively transported to the bloodstream. A non-limiting example of a receptor for active transport from the lung lumen to the bloodstream is the Fc receptor N (FcRn). One aspect of the invention includes the VHH molecules identified by the method.

15

20

Such VHH can then be used as a carrier VHH for the delivery of a therapeutic VHH to the corresponding target in the bloodstream upon nasal administration.

One embodiment of the present invention is a polypeptide construct as disclosed herein for use in treating, preventing and/or alleviating the symptoms of disorders relating to platelet-mediated aggregation or dysfunction thereof. Said disorders include thrombotic thrombocytopenic purpura (TTP), transient cerebral ischemic attack, unstable or stable angina pectoris, cerebral infarction, myocardial infarction, peripheral arterial occlusive disease, restenosis. Said disorders further include those arising from coronary by-pass graft, coronary artery valve replacement and coronary interventions such angioplasty, stenting, or atherectomy.

25

30

Other disorders are any of the formation of a non-occlusive thrombus, the formation of an occlusive thrombus, arterial thrombus formation, acute coronary occlusion, restenosis,

restenosis after PCTA or stenting, thrombus formation in stenosed arteries, hyperplasia after angioplasty, atherectomy or arterial stenting, occlusive syndrome in a vascular system or lack of patency of diseased arteries.

5 One aspect of the invention is a polypeptide construct as disclosed herein for use in the treatment, prevention and/or alleviation of disorders or conditions relating to platelet-mediated aggregation or dysfunction thereof, wherein said polypeptide construct is administered intravenously, subcutaneously, orally, sublingually, topically, nasally, vaginally, rectally or by inhalation.

10 Another aspect of the invention is the use of a polypeptide construct as disclosed herein for the preparation of a medicament for the treatment, prevention and/or alleviation of disorders or conditions relating to platelet-mediated aggregation or dysfunction thereof, wherein said polypeptide construct is administered intravenously, subcutaneously, orally, sublingually,
15 topically, nasally, vaginally, rectally or by inhalation.

Another aspect of the invention is a method of treating, preventing and/or alleviating disorders or conditions relating to relating to platelet-mediated aggregation or dysfunction thereof, comprising administering to a subject a polypeptide construct as disclosed herein, wherein
20 said heterospecific polypeptide construct is administered intravenously, subcutaneously, orally, sublingually, topically, nasally, vaginally, rectally or by inhalation.

Another aspect of the invention is a polypeptide construct as disclosed herein for use in the treatment, prevention and/or alleviation of disorders or conditions relating to platelet-mediated
25 aggregation or dysfunction thereof.

Another aspect of the invention is a use of a polypeptide as disclosed herein for the preparation of a medicament for the treatment, prevention and/or alleviation of disorders or conditions relating to platelet-mediated aggregation or dysfunction thereof.

30 One can use a polypeptide construct of the present invention in order to screen for agents that modulate the binding of the polypeptide to a vWF (or gplb or collagen). When identified in an assay that measures binding or said polypeptide displacement alone, agents will have

to be subjected to functional testing to determine whether they act as modulators of platelet-mediated aggregation.

In an example of a displacement experiment, phage or cells expressing vWF or a fragment thereof are incubated in binding buffer with, for example, a polypeptide represented by SEQ ID NO: 1 which has been labeled, in the presence or absence of increasing concentrations of a candidate modulator. To validate and calibrate the assay, control competition reactions using increasing concentrations of said polypeptide and which is unlabeled, can be performed. After incubation, cells are washed extensively, and bound, labelled polypeptide is measured as appropriate for the given label (e.g., scintillation counting, fluorescence, etc.). A decrease of at least 10% in the amount of labelled polypeptide bound in the presence of candidate modulator indicates displacement of binding by the candidate modulator. Candidate modulators are considered to bind specifically in this or other assays described herein if they displace 50% of labelled polypeptide (sub-saturating polypeptide dose) at a concentration of 1 μ M or less. Of course, the above method might easily be applied to screening for candidate modulators which alter the binding between the polypeptides represented by SEQ ID NOs: 2 to 15, 20 to 47 or the polypeptide constructs disclosed herein, and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gplb or collagen, or a fragment thereof.

Alternatively, binding or displacement of binding can be monitored by surface plasmon resonance (SPR). Surface plasmon resonance assays can be used as a quantitative method to measure binding between two molecules by the change in mass near an immobilized sensor caused by the binding or loss of binding of, for example, the polypeptide represented by SEQ ID NO: 1 from the aqueous phase to a vWF, or fragment thereof immobilized in a membrane on the sensor. This change in mass is measured as resonance units versus time after injection or removal of the said polypeptide or candidate modulator and is measured using a Biacore Biosensor (Biacore AB). vWF, or fragment thereof can be for example immobilized on a sensor chip (for example, research grade CM5 chip; Biacore AB) in a thin film lipid membrane according to methods described by Salamon et al. (Salamon *et al.*, 1996, Biophys J. 71: 283-294; Salamon *et al.*, 2001, Biophys. J. 80: 1557-1567; Salamon *et al.*, 1999, Trends Biochem. Sci. 24: 213-219, each of which is incorporated herein by reference.). Sarrio *et al.* demonstrated that SPR can be used to detect ligand binding to the GPCR A(1)

adenosine receptor immobilized in a lipid layer on the chip (Sarrío *et al.*, 2000, Mol. Cell. Biol. 20: 5164-5174, incorporated herein by reference). Conditions for the binding of a polypeptide construct of the invention in an SPR assay can be fine-tuned by one of skill in the art using the conditions reported by Sarrío *et al.* as a starting point. Of course, the above method might easily be applied to screening for candidate modulators which alter the binding between the polypeptide constructs disclosed herein and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gplb or collagen, or a fragment thereof.

10 SPR can assay for modulators of binding in at least two ways. First, a polypeptide represented by SEQ ID NO: 1, for example, can be pre-bound to immobilized vWF, or fragment thereof, followed by injection of candidate modulator at a concentration ranging from 0.1 nM to 1 μ M. Displacement of the bound polypeptide can be quantitated, permitting detection of modulator binding. Alternatively, the membrane-bound vWF, or fragment thereof
15 can be pre-incubated with a candidate modulator and challenged with, for example, a polypeptide represented by SEQ ID NO: 1. A difference in binding affinity between said polypeptide and vWF, or fragment thereof pre-incubated with the modulator, compared with that between said polypeptide and vWF, or fragment thereof in absence of the modulator will demonstrate binding or displacement of said polypeptide in the presence of modulator. In
20 either assay, a decrease of 10% or more in the amount of said polypeptide bound in the presence of candidate modulator, relative to the amount of said polypeptide bound in the absence of candidate modulator indicates that the candidate modulator inhibits the interaction of vWF, or fragment thereof and said polypeptide. Of course, the above method might easily be applied to screening for candidate modulators which alter the binding between the
25 polypeptides represented by SEQ ID NOs: 2 to 15, 20 to 47 or the polypeptide constructs disclosed herein, and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gplb, or collagen, or a fragment thereof.

Another method of detecting inhibition of binding of, for example, a polypeptide represented
30 by SEQ ID NOs: 1 to 7, to vWF, or fragment thereof uses fluorescence resonance energy transfer (FRET). FRET is a quantum mechanical phenomenon that occurs between a fluorescence donor (D) and a fluorescence acceptor (A) in close proximity to each other (usually < 100 Å of separation) if the emission spectrum of D overlaps with the excitation

spectrum of A. The molecules to be tested, e.g. a polypeptide represented by SEQ ID NO: 1 and a vWF, or fragment thereof, are labelled with a complementary pair of donor and acceptor fluorophores. While bound closely together by the vWF : polypeptide interaction, the fluorescence emitted upon excitation of the donor fluorophore will have a different wavelength from that emitted in response to that excitation wavelength when the said polypeptide and vWF, or fragment thereof are not bound, providing for quantitation of bound versus unbound molecules by measurement of emission intensity at each wavelength. Donor fluorophores with which to label the vWF, or fragment thereof are well known in the art. Of particular interest are variants of the A. Victoria GFP known as Cyan FP (CFP, Donor (D)) and Yellow FP (YFP, Acceptor (A)). As an example, the YFP variant can be made as a fusion protein with vWF, or fragment thereof. Vectors for the expression of GFP variants as fusions (Clontech) as well as fluorophore-labeled reagents (Molecular Probes) are known in the art. The addition of a candidate modulator to the mixture of fluorescently-labelled polypeptide and YFP-vWF will result in an inhibition of energy transfer evidenced by, for example, a decrease in YFP fluorescence relative to a sample without the candidate modulator. In an assay using FRET for the detection of vWF : polypeptide interaction, a 10% or greater decrease in the intensity of fluorescent emission at the acceptor wavelength in samples containing a candidate modulator, relative to samples without the candidate modulator, indicates that the candidate modulator inhibits the vWF:polypeptide interaction. Of course, the above method might easily be applied to screening for candidate modulators which alter the binding between the polypeptides represented by SEQ ID NOs: 2 to 15, 20 to 47 or the polypeptide constructs disclosed herein, and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gplb or collagen, or a fragment thereof.

25 A variation on FRET uses fluorescence quenching to monitor molecular interactions. One molecule in the interacting pair can be labeled with a fluorophore, and the other with a molecule that quenches the fluorescence of the fluorophore when brought into close apposition with it. A change in fluorescence upon excitation is indicative of a change in the association of the molecules tagged with the fluorophore:quencher pair. Generally, an increase in fluorescence of the labeled vWF, or fragment thereof is indicative that the polypeptide molecule (e.g. a polypeptide construct of the invention) bearing the quencher has been displaced. For quenching assays, a 10% or greater increase in the intensity of fluorescent emission in samples containing a candidate modulator, relative to samples

without the candidate modulator, indicates that the candidate modulator inhibits vWF : polypeptide interaction. Of course, the above method might easily be applied to screening for candidate modulators which alter the binding between the polypeptide constructs disclosed herein, and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gpIb or collagen, or a fragment thereof.

In addition to the surface plasmon resonance and FRET methods, fluorescence polarization measurement is useful to quantitate binding. The fluorescence polarization value for a fluorescently-tagged molecule depends on the rotational correlation time or tumbling rate. Complexes, such as those formed by vWF, or fragment thereof associating with a fluorescently labelled polypeptide (e.g. a fluorescently-labeled polypeptide represented by SEQ ID NOs: 1 to 15 and 20 to 47), have higher polarization values than uncomplexed, labeled polypeptide. The inclusion of a candidate inhibitor of the vWF:polypeptide interaction results in a decrease in fluorescence polarization, relative to a mixture without the candidate inhibitor, if the candidate inhibitor disrupts or inhibits the interaction of vWF, or fragment thereof with said polypeptide. Fluorescence polarization is well suited for the identification of small molecules that disrupt the formation of vWF: polypeptide complexes. A decrease of 10% or more in fluorescence polarization in samples containing a candidate modulator, relative to fluorescence polarization in a sample lacking the candidate modulator, indicates that the candidate modulator inhibits the vWF: polypeptide interaction. Of course, the above method might easily be applied to screening for candidate modulators which alter the binding between the polypeptide constructs disclosed herein, and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gpIb or collagen, or a fragment thereof.

Another alternative for monitoring vWF : polypeptide interactions uses a biosensor assay. ICS biosensors have been described in the art (Australian Membrane Biotechnology Research Institute; Cornell B, Braach-Maksyitis V, King L, Osman P, Raguse B, Wieczorek L, and Pace R. "A biosensor that uses ion-channel switches" Nature 1997, 387, 580). In this technology, the association of vWF, or fragment thereof and a polypeptide (e.g. a polypeptide represented by SEQ ID NOs: 1 to 15 and 20 to 47) is coupled to the closing of gramicidin-facilitated ion channels in suspended membrane bilayers and thus to a measurable change in the admittance (similar to impedance) of the biosensor. This approach

is linear over six orders of magnitude of admittance change and is ideally suited for large scale, high throughput screening of small molecule combinatorial libraries. A 10% or greater change (increase or decrease) in admittance in a sample containing a candidate modulator, relative to the admittance of a sample lacking the candidate modulator, indicates that the candidate modulator inhibits the interaction of vWF, or fragment thereof and said polypeptide. It is important to note that in assays testing the interaction of vWF, or fragment thereof with a polypeptide (such as for example, a polypeptide represented by SEQ ID NOs: 1 to 15 and 20 to 47), it is possible that a modulator of the interaction need not necessarily interact directly with the domain(s) of the proteins that physically interact with said polypeptide. It is also possible that a modulator will interact at a location removed from the site of interaction and cause, for example, a conformational change in the vWF. Modulators (inhibitors or agonists) that act in this manner are nonetheless of interest as agents to modulate platelet-mediated aggregation. Of course, the above method might easily be applied to screening for candidate modulators which alter the binding between the polypeptide constructs disclosed herein, and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gpIb or collagen, or a fragment thereof.

Any of the binding assays described can be used to determine the presence of an agent in a sample, e.g., a tissue sample, that binds to vWF, or fragment thereof, or that affects the binding of, for example, a polypeptide represented by SEQ ID NO: 1 to 15 or 20 to 47 to the vWF. To do so a vWF, or fragment thereof is reacted with said polypeptide in the presence or absence of the sample, and polypeptide binding is measured as appropriate for the binding assay being used. A decrease of 10% or more in the binding of said polypeptide indicates that the sample contains an agent that modulates the binding of said polypeptide to the vWF, or fragment thereof. Of course, the above generalised method might easily be applied to screening for candidate modulators which alter the binding between the polypeptide constructs disclosed herein, and macromolecules involved in platelet-mediated aggregation such as, for example, vWF, gpIb or collagen, or a fragment thereof.

30 Cells

A cell that is useful according to the invention is preferably selected from the group consisting of bacterial cells such as, for example, *E. coli*, yeast cells such as, for example, *S. cerevisiae*, *P. pastoris*, insect cells or mammalian cells.

A cell that is useful according to the invention can be any cell into which a nucleic acid sequence encoding a polypeptide comprising SEQ ID NOs: 1 to 47 or a polypeptide construct of the invention according to the invention can be introduced such that the polypeptide is expressed at natural levels or above natural levels, as defined herein. Preferably a polypeptide of the invention that is expressed in a cell exhibits normal or near normal pharmacology, as defined herein. Most preferably a polypeptide of the invention that is expressed in a cell comprises the nucleotide sequence capable of encoding the amino acid sequences presented in Table 30 or capable of encoding a amino acid sequence that is at least 70% identical to the amino acid sequence presented in Table 30.

According to a preferred embodiment of the present invention, a cell is selected from the group consisting of COS7-cells, a CHO cell, a LM (TK-) cell, a NIH-3T3 cell, HEK-293 cell, K-562 cell or a 1321N1 astrocytoma cell but also other transfectable cell lines.

In general, "therapeutically effective amount", "therapeutically effective dose" and "effective amount" means the amount needed to achieve the desired result or results (treating or preventing platelet aggregation). One of ordinary skill in the art will recognize that the potency and, therefore, an "effective amount" can vary for the various compounds that inhibit platelet-mediated aggregation used in the invention. One skilled in the art can readily assess the potency of the compound.

As used herein, the term "compound" refers the polypeptide constructs disclosed herein, or to a nucleic acid capable of encoding said polypeptide, or an agent identified according to the screening method described herein or said polypeptide comprising one or more derivatised amino acids.

By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, *i.e.*, the material may be administered to an individual along with the compound without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

The invention disclosed herein is useful for treating or preventing a condition of platelet-mediated aggregation, in a subject and comprising administering a pharmaceutically effective amount of a compound or composition that inhibits BTK and that inhibits platelet-mediated aggregation.

5

The invention disclosed herein is useful for treating or preventing the first steps of thrombus formation, in a subject and comprising administering a pharmaceutically effective amount of a compound or composition according to the invention.

- 10 The invention disclosed herein is useful for treating or preventing restenosis, in a subject and comprising administering a pharmaceutically effective amount of a compound or composition according to the invention.

- 15 One aspect of the present invention is the use of compounds of the invention for treating or preventing a condition of platelet-mediated aggregation, in a subject and comprising administering a pharmaceutically effective amount of a compound in combination with another, such as, for example, aspirin.

- 20 One aspect of the present invention is the use of compounds of the invention for treating or preventing a condition of platelet-mediated aggregation, in a subject and comprising administering a pharmaceutically effective amount of a compound in combination with another, such as, for example, a thrombolytic agent.

- 25 Another aspect of the present invention is a use of a compound of the invention for treating or preventing plaque or thrombus in an individual. Said plaque or thrombus formation may be under conditions of high shear. In both thrombosis and reocclusion, the reversible adhesion or tethering of the platelets at high shear rate is followed by a firm adhesion through the collagen receptor on platelets resulting in platelet activation; the tethering of platelets by vWF to collagen exposed in the damaged vessel wall is especially important under high shear
- 30 conditions. The inventors have found that polypeptide constructs of the present invention unexpectedly performed well under high shear conditions (e.g. Example 16.)

The present invention is not limited to the administration of formulations comprising a single compound of the invention. It is within the scope of the invention to provide combination treatments wherein a formulation is administered to a patient in need thereof that comprises more than one compound of the invention.

5

Conditions of platelet-mediated aggregation include, but are not limited to, unstable angina, stable angina, angina pectoris, embolus formation, deep vein thrombosis, hemolytic uremic syndrome, hemolytic anemia, acute renal failure, thrombolytic complications, thrombotic thrombocytopenic purpura, disseminated intravascular coagulopathy, thrombosis, coronary heart disease, thromboembolic complications, myocardial infarction, restenosis, and atrial thrombosis formation in atrial fibrillation, chronic unstable angina, transient ischemic attacks and strokes, peripheral vascular disease, arterial thrombosis, pre-eclampsia, embolism, restenosis and/or thrombosis following angioplasty, carotid endarterectomy, anastomosis of vascular grafts, and chronic exposure to cardiovascular devices. Such conditions may also result from thromboembolism and reocclusion during and after thrombolytic therapy, after angioplasty, and after coronary artery bypass.

15

It is well known in the art how to determine the inhibition of platelet-mediated aggregation using the standard tests described herein, or using other similar tests. Preferably, the method would result in at least a 10% reduction in platelet-mediated aggregation, including, for example, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount in between, more preferably by 90%.

20

Similarly, the method would result in at least a 10% reduction in intracellular calcium mobilisation including, for example, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%. Similarly, the method would result in at least a 10% reduction in the level of phosphorylated PLC γ 2 including, for example, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%.

25

The reduction can be measured, for example, by comparing the optical impedance in a chronology platelet aggregometer. Any other known measurement method may also be used. For example, (1) upon collagen stimulation, the level of collagen-induced intracellular calcium mobilization increases over time and so the measurement may include measuring the level of

30

collagen-induced intracellular calcium or (2) upon collagen stimulation, the level of phosphorylated PLCg 2 increases over time and so the measurement may include measuring the level of phosphorylated PLCg 2.

5 The cells can be contacted *in vitro*, for example, by adding a compound of the invention to the culture medium (by continuous infusion, by bolus delivery, or by changing the medium to a medium that contains the compound) or by adding the compound to the extracellular fluid *in vivo* (by local delivery, systemic delivery, inhalation, intravenous injection, bolus delivery, or continuous infusion). The duration of "contact" with a cell or population of cells is determined
10 by the time the compound is present at physiologically effective levels or at presumed physiologically effective levels in the medium or extracellular fluid bathing the cell or cells. Preferably, the duration of contact is 1-96 hours, and more preferably, for 24 hours, but such time would vary based on the half life of the compound and could be optimized by one skilled in the art using routine experimentation.

15 The compound useful in the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient or a domestic animal in a variety of forms adapted to the chosen route of administration, *i.e.*, orally or parenterally, by intra-nasally by inhalation, intravenous, intramuscular, topical or
20 subcutaneous routes.

The compound of the present invention can also be administered using gene therapy methods of delivery. See, *e.g.*, U.S. Patent No. 5,399,346, which is incorporated by reference in its entirety. Using a gene therapy method of delivery, primary cells transfected with the
25 gene for the compound of the present invention can additionally be transfected with tissue specific promoters to target specific organs, tissue, grafts, tumors, or cells.

Thus, the present compound may be systemically administered, *e.g.*, orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible
30 carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions,

5 syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

10 The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other
15 materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit
20 dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

25 The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

30 The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or

dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form must be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

15 Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional
20 desired ingredient present in the previously sterile-filtered solutions.

For topical administration, the present compound may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier,
25 which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, hydroxyalkyls or glycols or water-alcohol/glycol blends, in which the present compound can be dissolved or dispersed at
30 effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate

bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

Examples of useful dermatological compositions which can be used to deliver the compound to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Useful dosages of the compound can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

Generally, the concentration of the compound(s) in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.

The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician. Also the dosage of the compound varies depending on the target cell, tumor, tissue, graft, or organ.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

An administration regimen could include long-term, daily treatment. By "long-term" is meant at least two weeks and preferably, several weeks, months, or years of duration. Necessary modifications in this dosage range may be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein. See Remington's Pharmaceutical Sciences (Martin, E.W., ed. 4), Mack Publishing Co., Easton, PA. The dosage can also be
5 adjusted by the individual physician in the event of any complication.

The invention provides for an agent that is a modulator of platelet-mediated aggregation.

10

The candidate agent may be a synthetic agent, or a mixture of agents, or may be a natural product (e.g. a plant extract or culture supernatant). A candidate agent according to the invention includes a small molecule that can be synthesized, a natural extract, peptides, proteins, carbohydrates, lipids etc.

15

Candidate modulator agents from large libraries of synthetic or natural agents can be screened. Numerous means are currently used for random and directed synthesis of saccharide, peptide, and nucleic acid based agents. Synthetic agent libraries are commercially available from a number of companies including Maybridge Chemical Co.
20 (Trevillet, Cornwall, UK), Comgenex (Princeton, NJ), Brandon Associates (Merrimack, NH), and Microsource (New Milford, CT). A rare chemical library is available from Aldrich (Milwaukee, WI). Combinatorial libraries are available and can be prepared. Alternatively, libraries of natural agents in the form of bacterial, fungal, plant and animal extracts are available from e.g., Pan Laboratories (Bothell, WA) or MycoSearch (NC), or are readily
25 producible by methods well known in the art. Additionally, natural and synthetically produced libraries and agents are readily modified through conventional chemical, physical, and biochemical means.

30

Useful agents may be found within numerous chemical classes. Useful agents may be organic agents, or small organic agents. Small organic agents have a molecular weight of more than 50 yet less than about 2,500 daltons, preferably less than about 750, more preferably less than about 350 daltons. Exemplary classes include heterocycles, peptides, saccharides, steroids, and the like. The agents may be modified to enhance efficacy, stability,

pharmaceutical compatibility, and the like. Structural identification of an agent may be used to identify, generate, or screen additional agents. For example, where peptide agents are identified, they may be modified in a variety of ways to enhance their stability, such as using an unnatural amino acid, such as a D-amino acid, particularly D-alanine, by functionalizing the amino or carboxylic terminus, e.g. for the amino group, acylation or alkylation, and for the carboxyl group, esterification or amidification, or the like.

For primary screening, a useful concentration of a candidate agent according to the invention is from about 10 mM to about 100 μ M or more (i.e. 1 mM, 10 mM, 100 mM, 1 M etc.). The primary screening concentration will be used as an upper limit, along with nine additional concentrations, wherein the additional concentrations are determined by reducing the primary screening concentration at half-log intervals (e.g. for 9 more concentrations) for secondary screens or for generating concentration curves.

15 High throughput screening kit

A high throughput screening kit according to the invention comprises all the necessary means and media for performing the detection of an agent that modulates platelet-mediated aggregation by interacting with a target of the invention, such as for example vWF, or fragment thereof in the presence of a polypeptide (for example, a polypeptide represented by SEQ ID NOs: 1 to 15, 20 to 34, or a polypeptide construct), preferably at a concentration in the range of 1 μ M to 1 mM. The kit comprises the following. Recombinant cells of the invention, comprising and expressing the nucleotide sequence encoding vWF, or fragment thereof, which are grown according to the kit on a solid support, such as a microtiter plate, more preferably a 96 well microtiter plate, according to methods well known to the person skilled in the art especially as described in WO 00/02045. Alternatively vWF, or fragment thereof is supplied in a purified form to be immobilized on, for example, a 96 well microtiter plate by the person skilled in the art. Alternatively vWF, or fragment thereof is supplied in the kit pre-immobilized on, for example, a 96 well microtiter plate. Alternatively, in cases where the macromolecule to be screened against is gplb, gpla/IIa, or collagen, the above embodiments would carry gplb, gpla/IIa, or collagen polypeptide or polynucleic acid respectively in place of vWF. Kit may contain more than one macromolecule (e.g. vWF, gplb or collagen macromolecule and/or polynucleic acid). Modulator agents according to the invention, at concentrations from about 1 μ M to 1 mM or more, are added to defined wells in

the presence of an appropriate concentration of polypeptide construct said concentration of said polypeptide preferably in the range of 1 μ M to 1 mM. Kits may contain more than one polypeptide

- 5 Binding assays are performed as according to the methods already disclosed herein and the results are compared to the baseline level of, for example vWF, or fragment thereof binding to a polypeptide, such as, for example, a polypeptide represented by SEQ ID NOs: 2 to 15, 20 to 35, but in the absence of added modulator agent. Wells showing at least 2 fold, preferably 5 fold, more preferably 10 fold and most preferably a 100 fold or more increase or
10 decrease in vWF-polypeptide binding (for example) as compared to the level of activity in the absence of modulator, are selected for further analysis.

Other Kits Useful According to the Invention

- The invention provides for kits useful for screening for modulators of platelet-mediated
15 aggregation, as well as kits useful for diagnosis of diseases or disorders characterised by dysregulation platelet-mediated aggregation. Kits useful according to the invention can include an isolated vWF, or fragment thereof. Alternatively, or in addition, a kit can comprise cells transformed to express vWF, or fragment thereof. In a further embodiment, a kit according to the invention can comprise a polynucleotide encoding vWF, or fragment thereof.
20 In a still further embodiment, a kit according to the invention may comprise the specific primers useful for amplification of vWF, or fragment thereof. Alternatively, in cases where the macromolecule to be screened against is gplb, or collagen, the above embodiments would carry gplb, gpla/IIa, or collagen polypeptide or polynucleic acid, or fragment thereof respectively in place of vWF. Kit may contain more than one macromolecule (e.g. vWF, gplb,
25 or collagen macromolecule or polynucleic acid, or fragment thereof). Kits useful according to the invention can comprise an isolated polypeptide represented by SEQ ID NOs: 2 to 15, 20 to 47 7, a homologue thereof, or a functional portion thereof, or a polypeptide construct according to the invention. A kit according to the invention can comprise cells transformed to express said polypeptide. Kits may contain more than one polypeptide. In a further
30 embodiment, a kit according to the invention can comprise a polynucleotide encoding a macromolecule, for example, vWF, gplb, or collagen, or fragment thereof. In a still further embodiment, a kit according to the invention may comprise the specific primers useful for amplification of a macromolecule such as, for example, vWF gplb, or collagen, or fragment

thereof. All kits according to the invention will comprise the stated items or combinations of items and packaging materials therefore. Kits will also include instructions for use.

Medical devices

- 5 The invention also provides for invasive medical devices coated with a polypeptide construct of the invention or an agent resulting from a screening method of the invention for use in devices requiring the same. Non-limiting examples of devices include surgical tubing, occlusion devices, prosthetic devices. Application for said devices include surgical procedures which require a modulation of platelet-mediated aggregation around the site of
- 10 invasion.

One embodiment of the present is a method for treating invasive medical devices to prevent platelet-mediate aggregation around the site of invasion comprising the step of coating said device with a polypeptide construct or agent according to the invention.

- 15 Another embodiment of the present is a invasive medical devices that circumvents platelet-mediate aggregation around the site of invasion, wherein said device is coated with a polypeptide construct or agent according to the invention.

EXAMPLES

The invention is illustrated by the following non-limiting examples.

Legend to examples

- 5 **Example 1.** Immunization of llama002
- Example 2.** Repertoire cloning
- Example 3.** Rescue of the library, phage preparation
- Selection for binders for vWF inhibiting the interaction with collagen:**
- 10 **Example 4.** Selection for binders for vWF inhibiting the interaction with collagen first and
 second round of panning
- Example 5.** Functional characterization of vWF binders Inhibition of binding of vWF to
 collagen by VHH
- Example 6.** Expression and purification of VHH
- Example 7.** ELISA binding to vWF
- 15 **Example 8.** Specificity of the VHHs
- Example 9.** Inhibition ELISA with purified VHH
- Example 10.** Sequencing of the clones
- Example 11.** Epitope mapping
- Example 12.** Bivalent and bispecific VHHs expression and purification
- 20 **Example 13.** Binding in ELISA to vWF
- Example 14.** Inhibition ELISA with purified VHH
- Example 15.** Stability of bivalent or bispecific constructs in human plasma
- Example 16.** Evaluate inhibition by VHH at high shear.
- Selection of binders for vWF inhibiting the interaction with platelets:**
- 25 **Example 17.** Selection of binders for vWF inhibiting the interaction with platelets panning
- Example 18.** Screening for binding to the A1 domain of vWF
- Example 19.** Selection of binders for vWF inhibiting the interaction with platelets MATCHM
- Example 20.** ELISA binding to vWF of purified VHH
- Example 21.** Inhibition ELISA with purified VHH
- 30 **Example 22.** Sequencing of the clones
- Example 23.** Evaluate inhibition by VHH at high shear.
- Example 24.** Bivalent VHHs expression and purification
- Example 25.** Evaluate inhibition by VHH at high shear.

Make bispecific constructs for vWF-specific VHH:

Example 26. Construction and sequence of bispecific constructs

Example 27. Expression and purification of bispecific constructs

Example 28. Binding to vWF

- 5 **Example 29.** Inhibition of binding of vWF to collagen by the bispecific constructs as compared to the monovalent VHHs

Example 30. Evaluate inhibition by VHH at high shear.

Screening for binders for collagen type I and type III:

Example 31. Selection of binders for collagen type I

- 10 **Example 32.** Test VHH in ELISA for binding to collagen type I and type III.

Example 33. Sequencing of the clones

Example 34. Binding of purified VHH to collagen type I and type III

Example 35. Selection of binders for collagen type I inhibiting the interaction with vWF

Example 36. Test VHH in ELISA for binding to collagen type I and type III.

- 15 **Example 37.** Sequencing of the clones

Example 38. Binding of purified VHH to collagen type I and type III

Example 39. Test inhibition of binding of vWF to collagen by collagen-specific VHH in ELISA

Example 40. Test inhibition of platelet aggregation by collagen-specific VHH at low and at high shear

- 20 Improved half-life of VHH:

Example 41. Immunization of llamas

Example 42. Repertoire cloning

Example 43. Rescue of the library, phage preparation

Example 44. Phage ELISA

- 25 **Example 45.** Selection first and second round of biopanning

Example 46. Screening of individual clones after biopanning

Example 47. HinfI pattern and sequencing

Example 48. Test cross-reactivity with albumin of different species

Example 49. Expression and purification

- 30 **Example 50.** ELISA on MSA of the purified nanobodies

Example 51. Construction and sequence of bispecific constructs

Example 52. Expression and purification of bispecific constructs

Example 53. Functionality of both VHHs in the bispecific construct

Example 54. Inhibition of binding of vWF to collagen by the bispecific constructs as compared to the monovalent VHHs

Selection of binders for gplb inhibiting the interaction with vWF:

Example 55. Selection of binders for rgplb

5 **Example 56.** Screening for binders in ELISA.

Example 57. Binding of purified VHH to rgplb

Example 58. Sequencing of the clones

Example 59. Test inhibitory properties of VHHs specific for gplb

Example 60. Evaluate inhibition by VHH at high shear.

10 Coating of stents, tubings, balloons, catheters, transplantation material with VHH:

Example 61. Stability of VHH

Example 62. VHH immobilized in a polymer

Humanisation of C37:

Example 63. Alignment of C37 with DP-47

15 **Example 64.** Mutagenesis of C37

Fragments of anti-VWF VHHs

Example 65. Expression of a VHH-CDR3 fragment of vWF-C37

Examples

20 **Example 1: Immunization of llama002**

One llama was immunized with a cocktail of vWF and collagen type I and type III. Those antigens are all involved in the first interactions leading to platelet aggregation (Figure 1). The immunization scheme is summarized in Table 1

25 **Example 2: Repertoire cloning**

Peripheral blood lymphocytes (PBLs) were isolated by centrifugation on a density gradient (Ficoll-Paque Plus Amersham Biosciences). PBLs were used to extract total RNA (Chomczynski and Sacchi 1987). cDNA was prepared on 100 µg total RNA with MMLV Reverse Transcriptase (Gibco BRL) using oligo d(T) oligonucleotides. The cDNA was purified
30 with a phenol/chloroform extraction, followed by an ethanol precipitation and subsequently used as template to amplify the VHH repertoire.

In a first PCR, the repertoire of both conventional (1.6 kb) and heavy-chain (1.3 kb) antibody gene segments were amplified using a leader specific primer (5' -

GGCTGAGCTCGGTGGTCCTGGCT- 3') and the oligo d(T) primer (5'-AACTGGAAGAATTGCGGCCGCAGGAATTTTTTTTTTTTTTTT-3'). The resulting DNA fragments were separated by agarose gel electrophoresis and the 1.3 kb fragment, encoding heavy-chain antibody segments was purified from the agarose gel. A second PCR was performed using a mixture of FR1 reverse primers and the same oligo d(T) forward primer. The PCR products were digested with *Sfi*I (introduced in the FR1 primer) and *Bst*EII (naturally occurring in FR4). Following gel electrophoresis, the DNA fragment of approximately 400 basepairs were purified from gel and ligated into the corresponding restriction sites of phagemid pAX004 to obtain a library of cloned VHHs after electroporation of *Escherichia coli* TG1. The size of the library was 1.4×10^7 cfu, and all clones contained insert of the correct size.

Example 3: Rescue of the library, phage preparation

The library was grown at 37°C in 10 ml 2xTY medium containing 2% glucose, and 100 µg/ml ampicillin, until the OD600nm reached 0.5. M13KO7 phages (10^{12}) were added and the mixture was incubated at 37°C for 2 x 30 minutes, first without shaking, then with shaking at 100 rpm. Cells were centrifuged for 10 minutes at 4500 rpm at room temperature. The bacterial pellet was resuspended in 50 ml of 2xTY medium containing 100 µg/ml ampicillin and 25 µg/ml kanamycin, and incubated overnight at 37°C with vigorously shaking at 250 rpm. The overnight cultures were centrifuged for 15 minutes at 10000 rpm at 4°C. Phages were PEG precipitated (20% poly-ethylene-glycol and 1.5 M NaCl) and centrifuged for 30 minutes at 10000 rpm. The pellet was resuspended in 20 ml PBS. Phages were again PEG precipitated and centrifuged for 30 minutes at 20000 rpm and 4°C. The pellet was dissolved in 5 ml PBS-1% casein. Phages were titrated by infection of TG1 cells at OD600nm= 0.5 and plating on LB agar plates containing 100 µg/ml ampicillin and 2% glucose. The number of transformants indicates the number of phages (= pfu). The phages were stored at -80°C with 15% glycerol.

Selection for binders for vWF inhibiting the interaction with collagen (Figure 2)

Example 4: Selection for binders for vWF inhibiting the interaction with collagen: first and second round of panning

A well in a microtiterplate was coated with 2 µg/ml vWF or with PBS containing 1% casein. After overnight incubation at 4°C, the wells were blocked with PBS containing 1% casein, for

3 hours at RT. 200 μ l phages was added to the wells. After 2 hours incubation at RT, the wells were washed 10x with PBS-Tween and 10x with PBS. Phages were specifically eluted with 100 μ l of 100 μ g/ml collagen type III. Elutions were performed for overnight at room temperature. Eluted phages were allowed to infect exponentially growing TG1 cells, and were then plated on LB agar plates containing 100 μ g/ml ampicillin and 2% glucose. This experiment was repeated for a second round of panning, under the same conditions as described above. The results from the panning are presented in Table 2.

Example 5: Functional characterization of vWF binders: Inhibition of binding of vWF to collagen by VHH

A microtiter plate was coated overnight at 4°C with collagen type III at 25 μ g/ml in PBS. The plate was washed five times with PBS-Tween and blocked for 2 hours at room temperature with PBS containing 1% casein. The plate was washed five times with PBS-tween. 100 μ l of 2 μ g/ml vWF (vWF is pre-incubated at 37°C for 15 minutes) was mixed with 20 μ l periplasmic extract containing a VHH antibody (described in Example 6) and incubated for 90 minutes at room temperature in the wells of the microtiterplate. The plate was washed five times with PBS-tween. An anti-vWF-HRP monoclonal antibody (DAKO) was diluted 3,000-fold in PBS and incubated for 1 hour. The plate was washed five times with PBS-Tween and vWF-binding was detected with ABTS/H₂O₂. Signals were measured after 30 minutes at 405 nm. The results are presented in Table 3, showing that inhibitors are obtained after the first and second round of panning.

Example 6: Expression and purification of VHH

Plasmid was prepared for binders for vWF inhibiting the interaction with collagen type III and was transformed into WK6 electrocompetent cells. A single colony was used to start an overnight culture in LB containing 2% glucose and 100 μ g/ml ampicillin. This overnight culture was diluted 100-fold in 300 ml TB medium containing 100 μ g/ml ampicillin, and incubated at 37°C until OD_{600nm} = 0.5. 1 mM IPTG was added and the culture was incubated for 3 more hours at 37°C or overnight at 28°C.

Cultures were centrifuged for 20 minutes at 10000 rpm at 4°C. The pellet was frozen overnight or for 1 hour at -20°C. Next, the pellet was thawed at room temperature for 40 minutes, re-suspended in 20 ml PBS and shaken on ice for 1 hour. Periplasmic fraction was isolated by centrifugation for 20 minutes at 4°C at 20000 rpm. The supernatant containing the

VHH was loaded on Ni-NTA and purified to homogeneity. The yield of VHH was calculated according to the extinction coefficient. Results are summarized in Table 4.

Example 7: ELISA: binding to vWF

- 5 A microtiter plate was coated with 2 µg/ml vWF, overnight at 4°C. Plates were blocked for two hours at room temperature with 300 µl 1% casein in PBS. The plates were washed three times with PBS-Tween. Dilution series of all purified samples were incubated for 2 hours at RT. Plates were washed six times with PBS-Tween, after which binding of VHH was detected by incubation with mouse anti-myc mAB 1/2000 in PBS for 1 hour at RT followed by anti-
- 10 mouse-HRP conjugate 1/1000 in PBS, also for 1 hour at RT. Staining was performed with the substrate ABTS/H₂O₂ and the signals were measured after 30 minutes at 405 nm. The binding as a function of concentration of purified VHH is indicated in Figure 3.

Example 8: Specificity of the VHHs

- 15 Microtiterplates were coated with 2 µg/ml vWF and 3 other antigens not involved in platelet aggregation, but that were also immunized in llama 002. ELISA was performed as described in Example 7 with 670, 67 and 6.7 nM VHH. Results are summarized in Table 5. The results show that the inhibitory VHH are specific for vWF.

Example 9: Inhibition ELISA with purified VHH

- 20 Inhibition ELISA was performed as described in Example 5 but with decreasing concentrations of VHH and with human plasma at a dilution of 1/60 instead of with purified vWF or with human undiluted plasma. Results are represented in figure 4. The concentration of VHH resulting in 50% inhibition (IC₅₀) is given in Table 6.

25

Example 10: Sequencing of the clones

Clones were sequenced with M13 universal reverse primer. Amino acid sequences are shown in Table 30 (SEQ ID numbers 1, 3, 4, 5, 6 and 7).

Example 11: Epitope mapping

Cloning the A3 domain of vWF in pBAD-Opri-ss

The pBAD-Opri-strep-spec vector was used to display the VWF A3 domain as a fusion with Opri on the surface of UT5600 *E.coli* cells (F- ara-14 leuB6 azi-6 lacY1 proC14 tsx-67

entA403 trpE38 rfbD1 rpsL109 xyl-5 mtl-1 thi1 DompT fepC266) (Cote-Sierra et al, 1998, *Gene*, 221: 25-34). The gene coding for the A3 domain of vWF (201aa) was amplified by PCR using the A3for and A3back PCR primers.

5 A3for: CTG GTG CTG CAG AGG TGA AGC TTC GGA GAG GGG CTG CAG ATC
 A3back: ATC CAT GCA AAT CCT CTA GAA TCC AGA GCA CAG TTT GTG GAG

Fragment and vector were digested with HindIII and XbaI, ligated and transformed in UT5600 (= pBAD-vWFA1/pBAD-vWFA3). Transformed cells were plated on LB agar plates containing
 10 20 µg/ml streptomycin, 50 µg/ml spectinomycin.
 The pBAD-vWFA3 plasmid was transformed in UT5600 F- cells and plated on LB agar plates with 20 µg/ml streptomycin, 50 µg/ml spectinomycin. A single colony was used to inoculate LB medium with 20 µg/ml streptomycin, 50 µg/ml spectinomycin. Cells were grown overnight at 37°C at 200 rpm. The next day, cells were induced with 0.2% arabinose and incubated for
 15 1 more hour at 37°C at 150 rpm. Total cell lysates were boiled in reducing sample buffer, loaded on a 12% SDS-PAGE and transferred to nitrocellulose for Western blotting. Transferred proteins were detected using a monoclonal anti-Opri antibody (SH2.2) (Cote-Sierra et al, 1998, *Gene*, 221: 25-34). An anti-mouse IgG conjugated with alkaline phosphatase was applied (Sigma), and the blots were developed with BCIP/NBT (Figure 5).
 20 The pBAD-vWF-A3 plasmids were transformed in UT5600 F- cells and plated on LB agar plates with 20 µg/ml streptomycin, 50 µg/ml spectinomycin. A single colony was used to inoculate LB medium with 20 µg/ml streptomycin, 50 µg/ml spectinomycin. Cells were grown overnight at 37°C at 200 rpm. The next day, cells were induced with 0.2% arabinose and incubated for 1 more hour at 37°C at 150 rpm. A microtiter plate was coated overnight at 4°C
 25 with the monoclonal anti-Opri antibody (SH2.2) diluted 1/1000 in PBS and blocked for 2 hours at RT with PBS containing 1% casein. After induction, total cells were allowed to bind to the plate for 1 hour at room temperature. The plates were washed five times with PBS-Tween. Phage preparations of single colonies were allowed to bind for two hours at room temperature. The plates were washed five times with PBS-Tween. An anti-M13 HRP
 30 conjugate was used for detection of phage binding to *E. coli* cells expressing the A3 domain or to an irrelevant antigen on their surface. The plates were washed five times with PBS-Tween. Staining was performed with ABTS/H₂O₂ and signals were measured after 30 minutes at 405 nm. Results are summarized in Table 7.

Example 12: Bivalent and bispecific VHHs: expression and purification

The *E. coli* production vector pAX11 was designed (Figure 6), which allows the two-step cloning of bivalent or bispecific VHH.

5 The carboxy terminal VHH is cloned first with PstI and BstEII, while in the second step the other VHH is inserted by SfiI and NotI, which do not cut within the first gene fragment. The procedure avoids the enforcement of new sites by amplification and thus the risk of introducing PCR errors. The sequence is shown in Table 30 (SEQ ID numbers 8, 9, 10, 11 and 12).

10 Protein was expressed and purified as described in Example 6. An extra purification step was needed on superdex 75 for removal of some monovalent degradation product (5-10%). Yields obtained for 1 liter expression and purification of bivalent protein in *E. coli* are summarized in Table 8.

Example 13: Binding in ELISA to vWF

15 Binding to vWF was tested in ELISA as described in Example 7 and compared to binding of monovalent VHH. The results are shown in Figure 7. It is clear from the results that bivalent and bispecific VHH show stronger binding to VWF when compared to monovalent VHH.

Example 14: Inhibition ELISA with purified VHH

20 Inhibition for binding of vWF to collagen was tested for monovalent as compared to bivalent VHHs as described in Example 5. Instead of using purified vWF, human, baboon and pig plasma was used in parallel at a dilution of 1/60. IC50 values are summarized in Table 9.

Example 15: Stability of bivalent or bispecific constructs in human plasma

25 Stability of bivalent constructs was tested by incubation at 37°C in human plasma. AM-4-15-3/AM2-75 was incubated in human plasma at a concentration of 38 µg/ml at 37°C. A sample was removed after 1, 2, 3, 6 and 24 hours incubation. Samples were diluted 10-fold and analyzed by Western blot. Results are summarized in Figure 8 and show that the bivalent construct is stable for at least 24 hours at 37°C in human plasma.

30

Example 16: Evaluation of inhibition by VHH at high shear.

Glass coverslips (18x18 mm, Menzel Gläser) were cleaned overnight by a chromosulfuric acid (2% chromium trioxide) solution and rinsed with distilled water before spraying.

Monomeric collagen type III was solubilized in 50 mmol/L acetic acid and sprayed with a density of 30 $\mu\text{g}/\text{cm}^2$ on glass coverslips with a retouching airbrush (Badger model 100, Badger Brush Co). After the spraying procedure, the collagen surface was blocked for 1 hour with 1% human albumin in PBS (10 mmol/L phosphate buffer, pH 7.4, and 0.15 mol/L NaCl) to prevent nonspecific protein binding during the subsequent perfusion. Perfusion studies over collagen type III were carried out in a specially devised small parallel-plate perfusion chamber with well-defined rheological characteristics accommodating a glass coverslip. Whole blood was obtained by venipuncture from volunteers. Blood was drawn through the perfusion chamber by a Harvard infusion pump (pump 22, model 2400-004; Harvard, Natick, MA). The perfusion time was 5 minutes. Triplicate coverslips were inserted in the chamber. Five milliliters of whole blood was pre-warmed at 37°C for 5 minutes with or without addition of VHH, and then recirculated through the chamber for 5 minutes at a wall shear rate of 300 s^{-1} or 1600 s^{-1} . The coverslips were removed, rinsed, fixed with 0.05% glutaraldehyde, dehydrated with methanol, and stained with May-Grünwald/Giemsa. Platelet adhesion was quantitated with a light microscope (1,000 \times magnification) connected to a computerized image analyzer (AMS 40-10, Saffron Walden, UK). Platelet adhesion was expressed as the percentage of the surface covered with platelets. Results are summarized in Table 10 and 11.

Selection of binders for vWF inhibiting the interaction with platelets (figure 9).

Example 17: Selection of binders for vWF inhibiting the interaction with platelets: panning

Immunotubes were coated with 2 $\mu\text{g}/\text{ml}$ vWF or with PBS containing 1% casein. After overnight incubation at 4°C, the tubes were blocked with PBS containing 1% casein, for 3 hours at RT. 200 μl phages were added to the immunotubes with a final volume of 2 ml in PBS. After 2 hours incubation at RT, the immunotubes were washed 10x with PBS-Tween and 10x with PBS. Bound phages were eluted with 2 ml 0.2 M glycine buffer pH= 2.4. Elutions were performed for 20 minutes at room temperature. Eluted phages were allowed to infect exponentially growing TG1 cells, and were then plated on LB agar plates containing 100 $\mu\text{g}/\text{ml}$ ampicillin and 2% glucose. The results from the panning are presented in Table 12.

Example 18: Screening for binding to the A1 domain of vWF

The pBAD-Opri1-strep-spec vector was used to display the VWF A1 domain as a fusion with Opri1 on the surface of UT5600 *E.coli* cells (F- ara-14 leuB6 azi-6 lacY1 proC14 tsx-67

entA403 trpE38 rfbD1 rpsL109 xyl-5 mtl-1 thi1 DompT fepC266) (Cote-Sierra et al, 1998, *Gene*, 221: 25-34). The gene coding for the A1 domain of vWF (219aa) was amplified by PCR using the A1for and A1back PCR primers.

5 A1for: CCG GTG AGC CCC ACC ACT CTA AGC TTG GAG GAC ATC TCG GAA CCG

A1back: CCC CAG GGT CGA AAC CCT CTA GAG CCC CGG GCC CAC AGT GAC

Fragment and vector were digested with HindIII and XbaI, ligated and transformed in UT5600 (= pBAD-vWFA1/pBAD-vWFA3). Transformed cells were plated on LB agar plates containing 20 µg/ml streptomycin, 50 µg/ml spectinomycin.

10

The pBAD-vWFA1 plasmid was transformed in UT5600 F- cells and plated on LB agar plates with 20 µg/ml streptomycin, 50 µg/ml spectinomycin. A single colony was used to inoculate LB medium with 20 µg/ml streptomycin, 50 µg/ml spectinomycin. Cells were grown overnight at 37°C at 200 rpm. The next day, cells were induced with 0.2% arabinose and incubated for 15 1 more hour at 37°C at 150 rpm. Total cell lysates were boiled in reducing sample buffer, loaded on a 12% SDS-PAGE and transferred to nitrocellulose for Western blotting. Transferred proteins were detected using a monoclonal anti-Opri antibody (SH2.2) (Cote-Sierra et al, 1998, *Gene*, 221: 25-34). An anti-mouse IgG conjugated with alkaline phosphatase was applied (Sigma), and the blots were developed with BCIP/NBT as shown in 20 Figure 10.

The ELISA was performed as described in Example 11. Results are summarized in Table 13. The results indicate that vWF-A1 domain-specific VHH are obtained.

25 **Example 19: Selection of binders for vWF inhibiting the interaction with platelets: MATCHM**

E.coli cells expressing the A1 domain of vWF (Example 18) were used for a MATCHM experiment: UT5600 cells transformed with pBAD-Opri-A1 were grown and induced with 0.2% arabinose. Cells were washed and incubated with the phages for 1 hour at RT. This 30 mixture was washed 7 times with PBS-Tween and phages were eluted with exponentially growing TG1 cells. We performed a first and a second round of selection. Results are summarized in Table 14.

Example 20: ELISA: binding to vWF of purified VHH

VHH specific for the A1 domain of vWF were expressed and purified as described in Example 6. Binding in ELISA to vWF was measured as described in Example 7. Results are shown in Figure 11.

5

Example 21: Inhibition ELISA with purified VHH

A microtiter plate was coated overnight at 4°C with an antibody specific for platelet receptor gplb at 5µg/ml in PBS. The plate was washed five times with PBS-Tween, and blocked with 300 µl PBS-1% casein for 2 hours at room temperature. The plate was washed 3 times with PBS-Tween. Platelet receptor gplb (gplb) was applied to the wells of the microtiter plate at a concentration of 1 µg/ml and allowed to bind for 2 hours at room temperature. The plate was washed five times with PBS-Tween. VHH (A38 (negative control) and A50 (vWF A1 binder)) was added at decreasing concentration. Plasma containing vWF was pre-incubated at a dilution of 1/128 at 37°C for 5 minutes. Risto was added at a final concentration of 760 µg/ml and added to the VHH. This mixture was incubated for 30 minutes at room temperature. 100 µl of this mixture was then applied to a microtiter plate well and incubated for 90 minutes at room temperature. The plate was washed five times with PBS-Tween. A anti-vWF-HRP monoclonal antibody was diluted 3.000-fold in PBS and incubated for 1 hour. The plate was washed five times with PBS-tween and vWF-binding was detected with ABTS/H₂O₂. Signals were measured after 30 minutes at 405 nm. Results are summarized in Figure 12.

10

15

20

Example 22: Sequencing of the clones

Clones were sequenced with M13 universal reverse primer. Amino acid sequences are shown in Table 30 (SEQ ID numbers 23, 24, 25, 26, 27, 28, 29, 30 and 31).

25

Example 23: Evaluate inhibition by VHH at high shear.

Shear experiments were performed as described in Example 16. Platelet adhesion was expressed as the percentage of the surface covered with platelets. Results are summarized in Table 15 and 16.

30

Example 24: Bivalent VHHs: expression and purification

Bivalent molecules were constructed as described in Example 12. The sequence is shown in Table 30 (SEQ ID numbers 32, 33 and 34).

Protein was expressed and purified as described in Example 6. An extra purification step was needed on superdex 75 for removal of some monovalent degradation product (5-10%).

Example 25: Evaluate inhibition by VHH at high shear.

- 5 Shear experiments were performed as described in Example 16. Platelet adhesion was expressed as the percentage of the surface covered with platelets. Results are summarized in Table 17 and 18.

Make bispecific constructs for vWF-specific VHH (Figure 13)

10 **Example 26: Construction and sequence of bispecific constructs**

Constructs were made as described in Example 12, with one VHH specific for vWF and inhibiting the interaction with collagen, and the second VHH also specific for vWF but inhibiting the interaction with platelet receptor gplb. Sequences are shown in Table 30 (SEQ ID NOs: 20, 21 and 22)

15

Example 27: Expression and purification of bispecific constructs

Protein was expressed and purified as described in Example 6. A extra purification step was needed on superdex 75 for removal of some monovalent degradation product (5-10%). Yields obtained for 1 liter expression and purification of bispecific protein in *E. coli* are summarized in Table 19.

20

Example 28: Binding to vWF

Binding to vWF was tested in ELISA as described in example 7. Results are shown in Figure 14.

25

Example 29: Inhibition of binding of vWF to collagen by the bispecific constructs as compared to the monovalent VHHs

Inhibition for binding of vWF to collagen was tested for monovalent as compared to bispecific constructs as described in example 5. IC50 values are summarized in Table 20.

30

Example 30: Evaluate inhibition by VHH at high shear.

Shear experiments were performed as described in Example 16. Platelet adhesion was expressed as the percentage of the surface covered with platelets. Results are summarized in Table 21 and 22.

5

Screening for binders for collagen type I and type III (Figure 15)**Example 31: Selection of binders for collagen type I**

A microtiterplate was coated with 25 µg/ml collagen type I. Phages were prepared as described in Example 3 and allowed to bind to the well of a microtiterplate that was blocked for 2 hours. After washing, phages were eluted with 0.1 M glycine buffer pH=4.5. Results are summarized in Table 23.

10

Example 32: Test VHH in ELISA for binding to collagen type I and type III.

Clones were tested for binding in ELISA as described in example 7 but then on collagen type I or type III coated wells at 25 µg/ml in PBS. The results are summarized in Table 24.

15

Example 33: Sequencing of the clones

Clones were sequenced with M13 universal reverse primer. Amino acid sequences are shown in Table 30 (SEQ ID numbers 35, 36 and 37).

20

Example 34: Binding of purified VHH to collagen type I and type III

VHH were expressed and purified as described in Example 6. A microtiterplate was coated with 25 µg/ml collagen type I or type III and blocked. Binders were applied in duplo dilutions and binding was detected as described in Example 7. Results are summarized in Figure 16.

25

Example 35: Selection of binders for collagen type I inhibiting the interaction with vWF

A microtiterplate was coated with 25 µg/ml collagen type I. Phages were prepared as described in Example 3 and allowed to bind to the well of a microtiterplate that was blocked for 2 hours. After washing, phages were eluted with 300 µg/ml vWF. A second and third round of selection were performed in the same way.

30

Example 36: Test VHH in ELISA for binding to collagen type I and type III.

Clones were tested for binding to collagen type I and type III in ELISA as described in Example 34.

5 Example 37: Sequencing of the clones

Clones were sequenced with M13 universal reverse primer.

Example 38: Binding of purified VHH to collagen type I and type III

VHH were expressed and purified as described in example 6. A microtiterplate was coated
10 with 25 µg/ml collagen type I or type III and blocked. Binders were applied in duplo dilutions and binding was detected as described in Example 34.

Example 39: Test inhibition of binding of vWF to collagen by collagen-specific VHH in ELISA

15 Inhibition was tested as described in Example 5.

Example 40: Test inhibition of platelet aggregation by collagen-specific VHH at low and at high shear

Shear experiments were performed as described in Example 16. Platelet adhesion was
20 expressed as the percentage of the surface covered with platelets.

Improved half-life of VHH

Example 41: Immunization of llamas

One llama was immunized with human serum albumin (HSA). The immunization scheme is
25 summarized in Table 25.

Example 42: Repertoire cloning

The library was prepared as described in Example 2. The size of the library was 2×10^7 cfu,
and all clones contained insert of the correct size.

30

Example 43: Rescue of the library, phage preparation

Phages were prepared as described in Example 3.

Example 44: Phage ELISA

A microtiter plate (Maxisorp) was coated overnight at 4°C with PBS-1% casein or with 5 µg/ml HSA (human serum albumin). The plate was washed 3 times with PBS-Tween (0.05% Tween20) and blocked for 2 hours at room temperature with 200 µl PBS-1% casein. The plate was washed five times with PBS-Tween. Phages were prepared as described above and applied to the wells in consecutive twofold dilutions. Plates were washed five times with PBS-Tween. Bound phage were detected with a mouse monoclonal antibody anti-M13 conjugated with horse radish peroxidase (HRP) diluted 1/2000 in PBS. The plates were washed five times with PBS-Tween. Staining was performed with ABTS/H₂O₂ and signals were measured after 30 minutes at 405 nm. Results are shown in Figure 17 and indicate the presence of HSA-specific nanobodies in the library.

Example 45: Selection: first and second round of biopanning

A well in a microtiterplate was coated with 10 µg/ml mouse serum albumin (MSA), or with PBS containing 1% casein. After overnight incubation at 4°C, the wells were blocked with PBS containing 1% casein, for 3 hours at RT. 200 µl phages was added to the wells. After 2 hours incubation at RT, the wells were washed 10x with PBS-Tween and 10x with PBS. Bound phages were eluted with 100 µl 0.2 M glycine buffer pH= 2.4. Elutions were performed for 20 minutes at room temperature. Eluted phages were allowed to infect exponentially growing *E. coli* TG1 cells, and were then plated on LB agar plates containing 100 µg/ml ampicillin and 2% glucose. A second round was performed with the same conditions as described above. Results are summarized in Table 26.

Example 46: Screening of individual clones after biopanning**ELISA: binding to human serum albumin (HSA) and mouse serum albumin (MSA)**

Periplasmic extract was prepared as described in Example 6.

A microtiter plate was coated with 5 µg/ml HSA, with 5 µg/ml mouse serum albumin (MSA) or with PBS-1% casein, overnight at 4°C. Plates were blocked for two hours at room temperature with 300 µl 1% casein in PBS. The plates were washed three times with PBS-Tween. Periplasmic fraction was prepared for 23 individual clones after the first and second round of selection, and allowed to bind to the wells of the microtiterplate. Plates were washed six times with PBS-Tween, after which binding of nanobody was detected by incubation with mouse anti-Histidine monoclonal antibody Serotec MCA 1396 (1/1000 dilution) in PBS for 1

hour at RT followed by anti-mouse-alkaline phosphatase conjugate 1/2000 in PBS, also for 1 hour at RT. Staining was performed with the substrate PNPP (p-nitrophenyl-phosphate, 2 mg/ml in 1M diethanolamine, 1mM Mg₂SO₄, pH9.8) and the signals were measured after 30 minutes at 405 nm. Results are summarized in Table 27.

5

Example 47: HinfI pattern and sequencing

A PCR was performed on positive clones after the second round of panning, with a set of primers binding to a sequence in the vector. The PCR product was digested with the restriction enzyme HinfI and loaded on a agarose gel. 4 clones were selected with a different HinfI-pattern for further evaluation. Those clones were sequenced, and results are summarized in Table 30 (SEQ ID numbers 16, 17, 18 and 19).

10

Example 48: Test cross-reactivity with albumin of different species

A SDS-PAGE was run for plasma (1/10 dilution) from different species (baboon, pig, hamster, human, rat, mouse and rabbit) and blotted on a nitrocellulose membrane. Phages were prepared for clones MSA 21, MSA 24, MSA 210, MSA212 and a irrelevant nanobody as described in Example 3. Phages were allowed to bind to the nitrocellulose blotted serum albumins and unbound phages were washed away. Binding was detected with a anti-M13 polyclonal antibody coupled to HRP. DAP was used as a substrate for detection. Results are shown in Figure 18.

15

20

From these results we can conclude that all 4 binders are cross-reactive between pig, human, mouse (less for MSA212) and hamster serum albumin. MSA 21 is also cross-reactive with rabbit serum albumin. With the irrelevant nanobody no binding was observed (not shown).

As a control experiment, a SDS-PAGE was run with the different plasma samples diluted 1/100 in PBS. The gel was stained with coomassie. We can conclude from Figure 19 that albumin levels in all plasma samples are high except for rabbit plasma, with low levels of albumin.

25

Example 49: Expression and purification

Protein was expressed and purified as described in Example 6.

30

Example 50: ELISA on MSA of the purified nanobodies

A microtiterplate was coated with 5 µg/ml MSA overnight at 4°C. After washing, the plate was blocked for 2 hours at RT with PBS-1% casein. Samples were applied in duplicate starting at a concentration of 2500 nM at 1/3 dilutions and allowed to bind for 2 hours at RT. A polyclonal rabbit anti-nanobody serum was added at 1/1000 (K208) for one hour at RT. Detection was with anti-rabbit alkaline phosphatase conjugate at 1/1000 and staining with PNPP. Results are shown in Figure 20.

Example 51: Construction and sequence of bispecific constructs

Bispecific constructs were prepared with the first VHH specific for albumin (MSA21) and the second VHH specific for vWF (Figure 21). Constructs were made as described in Example 12. Sequences are shown in Table 30 (SEQ ID numbers 13, 14 and 15)

Example 52: Expression and purification of bispecific constructs

Protein was expressed and purified as described in Example 6. An extra purification step was needed on superdex 75 for removal of some monovalent degradation product (5-10%).

Example 53: Functionality of both VHHs in the bispecific construct

A microtiterplate was coated with 5 µg/ml mouse serum albumin overnight at 4°C. After washing the plate, wells were blocked for 2 hours with PBS-1% casein. The bispecific proteins were allowed to bind to the wells for 2 hours at RT. After washing, human, dog and pig plasma was added at different dilutions and allowed to bind for 2 hours at RT. Binding of vWF was detected with anti-vWF-HRP from DAKO at 1/3000 dilution. Staining was performed with ABTS/H₂O₂. Results are shown in Figure 22 and indicate that functionality of both VHHs is retained in the bispecific construct.

Example 54: Inhibition of binding of vWF to collagen by the bispecific constructs as compared to the monovalent VHHs

Inhibition for binding of vWF to collagen was tested for monovalent as compared to bispecific constructs as described in Example 5. IC₅₀ values are summarized in Table 28. Results indicate that the inhibitory properties of the VHH are retained in the bispecific construct.

Selection of binders for gplb inhibiting the interaction with vWF (Figure 23)

Immunization, repertoire cloning and phage preparation were performed as described in Examples 1, 2, 3.

5 Example 55: Selection of binders for rgplb

A microtiterplate was coated with a mouse mAb against rgplb. The plate was blocked and rgplb was allowed to bind for 2 hours at RT at 5 µg/ml. The plate was washed. Phages were prepared as described above and allowed to bind to the wells of the microtiterplate. After washing, phages were eluted with 0.1 M glycine buffer pH=4.5. A second round of panning
10 was performed in the same way.

Example 56: Screening for binders in ELISA.

Periplasmic extract was prepared as described in Example 6.

The supernatant was applied to wells coated with mAb and subsequently gplb, as described
15 in Example 55. Dilution series of all purified samples were incubated for 2 hours at RT. Plates were washed six times with PBS-Tween, after which binding of VHH was detected by incubation with mouse anti-His-HRP mAb 1/2000 in PBS for 1 hour at RT followed by staining with the substrate ABTS/H₂O₂. The signals were measured after 30 minutes at 405 nm.

20 Example 57: Binding of purified VHH to rgplb

Periplasmic fraction was prepared as described in Example 6. The supernatant containing the VHH was loaded on Ni-NTA and purified to homogeneity. The yield of VHH was calculated according to the extinction coefficient. ELISA was performed as described in Example 55.

25 Example 58: Sequencing of the clones

Clones were sequenced with M13 universal reverse primer.

Example 59: Test inhibitory properties of VHHs specific for gplb

VHHs were tested for inhibition in ELISA as described in Example 21.

30

Example 60: Evaluate inhibition by VHH at high shear.

Shear experiments were performed as described in Example 16. Platelet adhesion was expressed as the percentage of the surface covered with platelets.

Coating of stents, tubings, balloons, catheters, transplantation material with VHH**Example 61: Stability of VHH**

VHH C37 was incubated at 37°C and inhibition of binding of vWF to collagen was measured at different time points by ELISA as described in Example 7. Results were compared to VHH stored at -20°C and are presented in Figure 24. Shown for comparison are the activities of a scFv against B3 antigen (Reiter et al, Protein Engineering, 1994, 7: 697-704), and said scFv modified by the introduction of a disulphide bond between framework residues 44 and 105 to enhance its stability (dsFv). The dsFv lost 40% of its activity after 60 hours incubation at 37°C. After one year of incubation at 37°C, C37 was analyzed for its inhibitory properties as compared to C37 stored in the freezer. The ELISA was performed as described in Example 5 with human plasma at a final dilution of 1/200. The results are shown in Figure 25 and indicate that functionality is fully retained (IC50 value of 0.085 versus 0.1 µg/ml for C37 stored at 37°C versus -20°C). Therefore, it is expected that VHH will have a long shelf-life.

Example 62: VHH immobilized in a polymer

A mixture was prepared of 0.5 ml of 30% acrylamide; 1 ml of 1M Tris pH= 7.5; 3.5 ml H₂O; 35 µl of 10% APS; 3.5 µl TEMED. In some wells, VHH C37 was added at a final concentration of 10 µg/ml. The mixture was allowed to polymerize in the wells of a 96-well plate for 3 hours at RT. Human plasma was added at different dilutions starting with undiluted plasma. After 1 hour incubation at RT, the plate was washed and anti-vWF-HRP (DAKO) was added at 1/2000, for 1 hour at RT. After washing the plate, substrate (ABTS/H₂O₂) was added and OD405nm was measured. The result is shown in Figure 26. The results indicate that VHH remain functional upon immobilization in a polymer.

Humanisation of C37**Example 63: Alignment of C37 with DP-47**

Alignment of the C37 nanobody (SEQ ID number 1) and a human VH3 germline (DP-47) revealed a high degree of homology:

- 4 AA changes in FR1 on position 1, 5, 28 and 30
- 4 AA changes in FR3 on position 74, 75, 84 and 94
- 3 AA changes in FR4 on position 104, 108 and 111

as is shown in Figure 27

Example 64: Mutagenesis of C37

C37 was mutated by using a non-PCR based site-directed mutagenesis method as described by Chen and Ruffner (Chen and Ruffner, Amplification of closed circular DNA in vitro, Nucleic Acids Research, 1998, 1126-1127) and commercialized by Stratagene (Quickchange site-directed mutagenesis).

Plasmid DNA was used as template in combination with 2 mutagenic primers (table 29) introducing the desired mutation(s). The 2 primers are each complementary to opposite strands of the template plasmid DNA. In a polymerase reaction using the *Pfu* DNA polymerase each strand is extended from the primer sequence during a cycling program using a limited amount of cycles. This results in a mixture of wild type and mutated strands. Digestion with *DpnI* results in selection of mutated *in vitro* synthesized DNA. The DNA was precipitated and transformed to *E. coli* and analyzed for the required mutation by sequence analysis. The clone with the correct sequence was named C37-hum, the amino acid sequence is in Table 30 SEQ ID number 2.

Expression and purification of C37-hum was performed as described in Example 6. Inhibition of binding of vWF to collagen for C37 was compared to C37-hum as described in Example 5. Results are shown in Figure 28. It clearly shows that the humanized version of C37 remains fully functional.

The positions that still need to be humanized are: Q1, Q5, D104, Q108 and I111. We can humanize position 1 and 5 without loss of inhibition since these amino acids were introduced by the FR1 primer and do not occur naturally in the llama sequence. We can also humanize position 111 since we isolated a VHH identical to C37 except for I111V (AM-2-75 SEQ ID number 3) with the same functional characteristics (Example 9 and Table 6).

Position 108 is solvent exposed in camelid VHH, while in human antibodies this position is buried at the VH-VL interface (Spinelli, 1996; Nieba, 1997). In isolated VHs position 108 is solvent exposed. The introduction of a non-polar hydrophobic Leu instead of polar uncharged Gln can have a drastic effect on the intrinsic foldability/stability of the molecule.

Fragments of anti-VWF VHHs**Example 65: Expression of a VHH-CDR3 fragment of vWF-C37**

5 The CDR3 region of C37 was amplified by using a sense primer located in the framework 4 region (Forward: CCCCTGGTCCCAGTTCCTC) and an anti-sense primer located in the framework 3 region (Reverse: TGTGCTCGCGGGGCCGTAC).

In order to clone the CDR-3 fragment in pAX10, a second round PCR amplification was performed with following primers introducing the required restriction sites:

Reverse primer Sfi1:

10 GTCCTCGCAACTGCGGCCCAGCCGGCCTGTGCTCGCGGGGCCGTAC

Forward primer Not1:

GTCCTCGCAACTGCGCGGCCGCCCCCTGGTCCCAGTTCCTC

15 The PCR reactions were performed in 50 ml reaction volume using 50pmol of each primer. The reaction conditions for the primary PCR were 11 min at 94 °C, followed by 30/60/120 sec at 94/55/72 °C for 30 cycles, and 5 min at 72°C. All reaction were performed wit 2.5 mM MgCl₂ , 200 mM dNTP and 1.25U AmpliTaq God DNA Polymerase (Roche Diagnostics, Brussels, Belgium).

After cleavage with Sfi1 and Not1 the PCR product was cloned in pAX10.

20

FIGURES

Figure 1. Interactions involved in the first steps of platelet aggregation.

25 **Figure 2.** Interactions involved in the first steps of platelet aggregation. A VHH is indicated inhibiting the interaction between vWF and collagen.

Figure 3. Binding to vWF as determined by ELISA, by purified VHH as described in Example 7.

Figure 4. ELISA to test inhibition by VHH of binding of vWF to collagen as described in Example 9.

30 **Figure 5.** Western blot showing expression of A3 domain of vWF as a fusion with Oprl on the surface of *E.coli* as described in Example 11.

Figure 6. Restriction map of multiple cloning site of PAX011 for construction of bivalent or bispecific nanobodies.

Figure 7. Binding in ELISA to purified vWF, for monovalent versus bivalent and bispecific VHH as described in Example 13.

Figure 8. Stability of bispecific VHH in human plasma upon incubation at 37°C for up to 24 hours as described in Example 15.

5 **Figure 9.** Interactions involved in the first steps of platelet aggregation. A VHH is indicated inhibiting the interaction between vWF and platelets.

Figure 10. Western blot showing expression of A1 domain of vWF as a fusion with Opr1 on the surface of *E.coli* as described in Example 18.

Figure 11. Binding to vWF as determined by ELISA, by purified VHH as described in
10 Example 20.

Figure 12. Inhibition of binding of gplb to VWF by A50 and A38 (negative control) as described in Example 21.

Figure 13. Interactions involved in the first steps of platelet aggregation. A bispecific constructs is indicated with one VHH specific for vWF and inhibiting the interaction between
15 vWF and collagen and the second VHH specific for vWF but inhibiting the interaction between vWF and platelets.

Figure 14. Binding in ELISA to vWF as described in Example 28.

Figure 15. Interactions involved in the first steps of platelet aggregation. A VHH is indicated specific for collagen and inhibiting the interaction between vWF and collagen.

20 **Figure 16.** Binding of purified VHH to collagen type I and type III in ELISA as described in Example 34.

Figure 17. Phage ELISA to show that HSA-specific nanobodies are present in the library as described in Example 44.

Figure 18. Binding of phages expressing the albumin binders, to plasma blotted on
25 nitrocellulose as described in Example 48.

Figure 19. Coomassie staining of plasma samples on SDS-PAGE as described in Example 48.

Figure 20. Binding of purified nanobodies to mouse albumin as determined by ELISA as described in Example 50.

30 **Figure 21.** Bispecific constructs with one VHH binding to albumin and a second VHH binding to vWF for improvement of half-life as described in Example 51.

Figure 22. Sandwich ELISA showing the functionality of both VHHs in a bispecific construct as described in Example 53.

Figure 23. Interactions involved in the first steps of platelet aggregation. A VHH is indicated specific for gplb and inhibiting the interaction between vWF and platelets.

Figure 24. Residual activity for C37 stored at -20°C as compared to C37 incubated at 37°C for up to 194 hours. C37 stability is compared to stability of a scFv specific for B3 antigen and a stabilized form, dsFv (stabilized by 2 disulphide bonds) as described in Example 61.

Figure 25. Inhibitory activity for C37 stored at -20°C as compared to C37 incubated at 37°C for 1 year as described in Example 61.

Figure 26. Binding of vWF from human plasma to C37 immobilized in acrylamide as described in Example 62.

Figure 27. Amino acid alignment of C37 with human germline sequence DP-47 as described in Example 63.

Figure 28. Inhibition of binding of vWF to collagen as determined by ELISA for C37 and C37 hum as described in Example 64.

TABLES

Table 1. Immunization scheme used for llama 002 according to Example 1.

Table 2. Plaque forming units (pfu) after one or two round(s) of panning on vWF as compared to PBS-casein as described in Example 4. Pfu vWF (antigen) divided by pfu casein (a specific binding) = enrichment.

Table 3. Number of inhibitors versus the number of clones tested after the first and the second round of panning as described in Example 5.

Table 4. Yield (mg/liter culture) after expression and purification of VHH grown in WK6 *E.coli* cells as described in Example 6.

Table 5. OD 405 nm for binding of VHH in ELISA to vWF and 3 antigens that were also immunized in llama002 according to Example 8.

Table 6. Concentration of VHH (nM) needed to inhibit binding of vWF to collagen by 50% (IC50) as described in Example 9.

Table 7. Epitope mapping of VHH binding to vWF and inhibiting the interaction with collagen as described in example 11.

Table 8. Yields of purified protein (mg) per liter of culture for bivalent and bispecific VHHs as described in Example 12.

Table 9. IC50 values for monovalent as compared to bivalent and bispecific VHHs. Inhibition was tested with human, pig and baboon plasma as described in Example 14.

Table 10. Inhibition of platelet aggregation at high shear (1600 s^{-1}) as described in Example 16.

5 **Table 11.** Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 16.

Table 12. Plaque forming units (pfu) after one round of panning on vWF as described in Example 17. Pfu vWF (antigen) divided by pfu casein (a-specific binding) = enrichment.

Table 13. Results of screening in ELISA of individual colonies for binding to vWF and to the A1 domain of vWF as described in Example 18.

10 **Table 14.** Results after one round of MATCHM on pBAD-Opri-A1 cells as described in Example 19.

Table 15. Inhibition of platelet aggregation at high shear (1600 s^{-1}) as described in Example 23.

Table 16. Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 23.

15 **Table 17.** Inhibition of platelet aggregation at high shear (1600 s^{-1}) as described in Example 25.

Table 18. Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 25.

Table 19. Yields after expression and purification of bispecific constructs as described in Example 27.

20 **Table 20.** IC50 values for bispecific nanobodies for the A1 and A3 domain of vWF as described in Example 29.

Table 21. Inhibition of platelet aggregation at high shear (1600 s^{-1}) as described in Example 30.

Table 22. Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 30.

25 **Table 23.** Plaque forming units (pfu) after one round of panning on collagen type I as described in Example 31. Pfu vWF (antigen) divided by pfu casein (a-specific binding) = enrichment.

Table 24. Number of clones binding to collagen type I and type III after one round of selection as described in Example 32.

30 **Table 25.** Immunization scheme for human serum albumin according to example 41.

Table 26. Results after one and two rounds of panning on mouse serum albumin as described in Example 45.

Table 27. Clones were selected after one and two rounds of selection and periplasmic extracts were prepared. These clones were analyzed in ELISA for binding to human and mouse albumin as described in Example 46.

Table 28. IC50 values for bispecific nanobodies against albumin and against vWF as described in Example 54.

Table 29. Sequences of the primers used for humanization of C37 as described in Example 64.

Table 30. Amino acid sequence listing of the peptides of the present invention and of human von Willebrand factor (vWF). The sequence of human vWF indicates A1 and A3 domains respectively in bold lettering.

Table 1: Immunization scheme used for llama 002 according to Example 1.

Llama002 Day of immunization	vWF	Collagen Type I	Collagen Type III
0	100 µg	100 µg	100 µg
7	100 µg	100 µg	100 µg
14	50 µg	50 µg	50 µg
21	50 µg	50 µg	50 µg
28	50 µg	50 µg	50 µg
35	50 µg	50 µg	50 µg

Table 2: Plaque forming units (pfu) after one or two round(s) of panning on vWF as compared to PBS-casein as described in example 4. Pfu vWF (antigen) divided by pfu casein (a specific binding) = enrichment.

round	Pfu vWF	Pfu casein	Enrichment
First	1×10^7	2.5×10^5	40
Second	5×10^8	2.5×10^6	200

Table 3: Number of inhibitors versus the number of clones tested after the first and the second round of panning as described in Example 5.

round	Number of inhibitors versus number of clones tested
First	4/800
Second	4/96

5 Table 4: Yield (mg/liter culture) after expression and purification of VHH grown in WK6 *E.coli* cells as described in Example 6.

Name VHH	Yield (mg/liter culture)
22-2L-34	1.4
T76	2.9
AM-4-15-3	2.2
22-4L-16	2.8
C37	3.8
AM-2-75	3.6

10 Table 5: OD 405 nm for binding of VHH in ELISA to vWF and 3 antigens that were also immunized in llama002 according to Example 8.

OD405 nm nM	vWF			Antigen 1			Antigen 2			Antigen 3		
	670	67	6.7	670	67	6.7	670	67	6.7	670	67	6.7
T76	0.77	0.36	0.13	0.05	0.05	0.05	0.06	0.06	0.04	0.04	0.04	0.03
22-2L-34	1.30	0.63	0.20	0.06	0.0	0.10	0.10	0.07	0.05	0.06	0.05	0.03
22-4L-16	1.41	0.86	0.81	0.08	0.10	0.11	0.15	0.11	0.05	0.08	0.07	0.03
C37	1.51	1.09	1.06	0.10	0.10	0.12	0.12	0.11	0.08	0.10	0.08	0.06
AM-2-75	1.57	1.10	1.04	0.09	0.11	0.12	0.14	0.11	0.09	0.10	0.13	0.05
AM-4-15-3	1.32	1.06	0.56	0.09	0.12	0.12	0.12	0.11	0.10	0.10	0.10	0.08

Table 6: Concentration of VHH (nM) needed to inhibit binding of vWF to collagen by 50% (IC50) as described in Example 9.

Name VHH	IC50 (nM) human plasma 1/60	IC50 (nM) undiluted human plasma
22-2L-34	10	-
T76	30	-
AM-4-15-3	7	200
22-4L-16	4	1000
C37	3	-
AM-2-75	2	100

5 Table 7: Epitope mapping of VHH binding to vWF and inhibiting the interaction with collagen as described in Example 11.

Name VHH	Binding to A3 domain of vWF
22-2L-34	Yes
T76	No
22-4L-16	No
C37	Yes
AM-2-75	Yes

Table 8: Yields of purified protein (mg) per liter of culture for bivalent and bispecific VHHs as described in Example 12.

NH2-terminal VHH	COOH-terminal VHH	Yield mg/liter culture
AM-2-75	AM-4-15-3	3.2
AM-4-15-3	AM-4-15-3	2.3
AM-4-15-3	AM-2-75	4.0
AM-2-75	AM-2-75	1.0
AM-2-75	22-4L-16	3.0

Table 9: IC₅₀ values for monovalent as compared to bivalent and bispecific VHHs. Inhibition was tested with human, pig and baboon plasma as described in Example 14.

First VHH	Second VHH	IC ₅₀ (ng/ml) human plasma	IC ₅₀ (ng/ml) baboon plasma	IC ₅₀ (ng/ml) pig plasma
AM-2-75		150	400	50
AM-4-15-3		50	200	40
22-4L-16		15	70	7
AM-2-75	AM-4-15-3	3	5	6
AM-4-15-3	AM-2-75	2	8	3
AM-4-15-3	AM-4-15-3	5	10	7
AM-2-75	22-4L-16	8	20	10
AM-2-75	AM-2-75	5		

5 Table 10: Inhibition of platelet aggregation at high shear (1600 s⁻¹) as described in Example 16.

	Concentration [μg/ml]	% inhibition
AM-2-75	0.2	0
AM-2-75	0.3	12
AM-2-75	0.4	56
AM-2-75	0.6	97
AM-2-75	0.8	96
AM-4-15-3	0.05	0
AM-4-15-3	0.1	75
AM-4-15-3	0.25	74
AM-4-15-3	0.5	86
AM-4-15-3	1	91
22-4L-16	0.1	32
22-4L-16	0.5	54
22-4L-16	0.75	86
22-4L-16	2	97
22-4L-16	10	99

AM-4-15-3/AM-4-15-3	0.05	0
AM-4-15-3/AM-4-15-3	0.075	23
AM-4-15-3/AM-4-15-3	0.1	37
AM-4-15-3/AM-4-15-3	0.15	56
AM-4-15-3/AM-4-15-3	0.2	98
AM-4-15-3/AM-4-15-3	1.9	100
AM-4-15-3/AM-2-75	1.9	100
AM-2-75/AM-4-15-3	0.05	2
AM-2-75/AM-4-15-3	0.1	36
AM-2-75/AM-4-15-3	0.2	96
AM-2-75/AM-4-15-3	0.35	91
AM-2-75/AM-4-15-3	0.4	98
AM-2-75/AM-2-75	0.04	5
AM-2-75/AM-2-75	0.1	26
AM-2-75/AM-2-75	0.2	52
AM-2-75/AM-2-75	0.3	80
AM-2-75/AM-2-75	0.4	99
AM-2-75/AM-2-75	0.83	100
AM-2-75/22-4L-16	1.17	99

Table 11: Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 16.

	Concentration [$\mu\text{g/ml}$]	% inhibition
AM-2-75	10	20
AM-4-15-3	10	17
22-4L-16	10	22
AM-4-15-3/AM-4-15-3	10	23
AM-4-15-3/AM-2-75	10	21
AM-2-75/AM-4-15-3	10	18
AM-2-75/AM-2-75	2	32
AM-2-75/22-4L-16	10	13

Table 12: Plaque forming units (pfu) after one round of panning on vWF as described in Example 17. Pfu vWF (antigen) divided by pfu casein (a-specific binding) = enrichment.

Pfu vWF	Pfu casein	Enrichment
1.5×10^7	1×10^4	1.500

- 5 Table 13: Results of screening in ELISA of individual colonies for binding to vWF and to the A1 domain of vWF as described in Example 18.

No. clones +ve for vWF / No. tested	No. clones +ve for A1 / No. tested
344/380	5/570

Table 14: Results after one round of MATCHM on pBAD-Opri-A1 cells as described in Example 19.

Round	No. clones +ve for vWF / No. tested	No. clones +ve for A1 / No. tested
First	-	1/96
second	45/348	12/348

10

Table 15: Inhibition of platelet aggregation at high shear (1600 s^{-1}) as described in Example 23.

	Concentration [$\mu\text{g/ml}$]	% inhibition
2A1-4L-129	13.5	26
2A1-4L-129	20	50
2L-A1-15	9.7	30
2L-A1-15	25	45
A50	10.2	20
2A1-4L-79	11.1	20
2A1-4L-34	11.1	3
Z29	10.6	0
I53	9.7	0
M53	10.6	0

Table 16: Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 23.

	Concentration [$\mu\text{g/ml}$]	% inhibition
2A1-4L-129	10	0
2L-A1-15	10	3
A50	25	0
2A1-4L-79	25	15

5 Table 17: Inhibition of platelet aggregation at high shear (1600 s^{-1}) as described in Example 25.

	Concentration [$\mu\text{g/ml}$]	% inhibition
2A1-4L-79/2A1-4L-79	25	54
2LA1-15/2LA1-15	25	45

Table 18: Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 25.

	Concentration [$\mu\text{g/ml}$]	% inhibition
2A1-4L-79/2A1-4L-79	25	0
2LA1-15/2LA1-15	25	23

10

Table 19: Yields after expression and purification of bispecific constructs as described in Example 27.

NH2 terminal VHH	COOH-terminal VHH	Yield mg/liter culture
2A1-4L-79	AM-4-15-3	7.5
2A1-4L-79	AM-2-75	2
2A1-4L-79	22-4L-16	2.5

Table 20: IC50 values for bispecific nanobodies for the A1 and A3 domain of vWF as described in example 29.

NH2-terminal VHH	COOH-terminal VHH	IC50 (ng/ml)
2A1-4L-79	AM-4-15-3	10
AM-4-15-3	-	45
2A1-4L-79	AM-2-75	12
AM-2-75	-	40
2A1-4L-79	22-4L-16	10
22-4L-16	-	10
2A1-4L-79	-	>10000

5 Table 21: Inhibition of platelet aggregation at high shear (1600 s^{-1}) as described in Example 30.

	Concentration [$\mu\text{g/ml}$]	% inhibition
2A1-4L-79/AM-4-15-3	12	100
2A1-4L-79/AM-2-75	0.02	0
2A1-4L-79/AM-2-75	0.1	28
2A1-4L-79/AM-2-75	0.5	79
2A1-4L-79/AM-2-75	1	95
2A1-4L-79/22-4L-16	12	96

Table 22: Inhibition of platelet aggregation at low shear (300 s^{-1}) as described in Example 30.

	Concentration [$\mu\text{g/ml}$]	% inhibition
2A1-4L-79/AM-4-15-3	10	15
2A1-4L-79/AM-2-75	10	25
2A1-4L-79/22-4L-16	10	27

Table 23: Plaque forming units (pfu) after one round of panning on collagen type I as described in Example 31. Pfu vWF (antigen) divided by pfu casein (a-specific binding) = enrichment.

Phages eluted from collagen type I	5×10^6
Phages eluted from casein	4×10^4
Enrichment	100

5

Table 24: Number of clones binding to collagen type I and type III after one round of selection as described in Example 32.

Collagen Type I	15/32
Collagen Type III	7/32
Casein	0/32

10 Table 25: Immunization scheme for human serum albumin according to Example 41.

Day of immunization	HSA Llama006
0	100 µg
7	100 µg
14	50 µg
21	50 µg
28	50 µg
35	50 µg

Table 26: Results after one and two rounds of panning on mouse serum albumin as described in Example 45.

	First round	Second round
Pfu mouse serum albumin	2.5×10^7	2.5×10^7
Pfu casein	5×10^3	2.5×10^3
Enrichment	5.000	10.000

15

Table 27: Clones were selected after one and two rounds of selection and periplasmic extracts were prepared. These clones were analyzed in ELISA for binding to human and mouse albumin as described in Example 46.

	First round	Second round
ELISA mouse serum albumin	1/16	15/16
ELISA human serum albumin	1/16	15/16
ELISA casein	0/16	0/16

5

Table 28: IC50 values for bispecific nanobides against albumin and against vWF as described in Example 54.

	IC50 (ng/ml)
AM-2-75	100
MSA21/AM-2-75	60
AM-4-15-3	155
MSA21/AM-4-15-3	245
22-4L-16	100
MSA21/22-4L-16	140

10 Table 29: Sequences of the primers used for humanization of C37 as described in Example 64.

Mutation	Template	Primer sequence
A74S+N75 K+P84A	Wild type	5' -AGA GAC AAC TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG AGA GCT GAG GAC ACG-3' Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
A74S+N75 K+P84A+R 94K	A74S+N75 K+P84A	5' -AT TAC TGT GCT AAA GGG GCC GGT ACT AGT T-3' Tyr Cys Ala Lys Gly Ala Gly Thr Ser
N28T+N30 S	A74S+N75 K+P84A+R	5' -TCC TGT GCA GCC TCC GGA TTC ACT TTC AGT TGG TA-3'

A74S+N75 K+P84A+R 94K	94K	Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Trp
-----------------------------	-----	---

Table 30: Amino acid sequence listing of the peptides of the present invention and of human von Willebrand factor (vWF). The sequence of human vWF indicates A1 and A3 domains respectively in bold lettering.

NAME	SEQ ID NO	SEQUENCE
		Anti-vWF A3 VHH
C37	1	QVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNANNTLYLQMNSLRPEDTAVYYCARGAGTSSY LPQRGWWDQGTQVTVSS
C37- hum	2	QVQLQESGGGLVQPGGSLRLSCAASGFTFSWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNKNTLYLQMNSLRPEDTAVYYCAKAGTSSY LPQRGWWDQGTQVTVSS
AM-2- 75	3	QVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNANNTLYLQMNSLRPEDTAVYYCARGAGTSSY LPQRGWWDQGTQVTVSS
22-2L- 34	4	QVQLQDSGGGLVQAGGSLRLSCAASVRIFTSYAMGWFRQAPGKREFVAAIN RSGKSTYYSDSVEGRFTISRDNKNTVSLQMDSLKLEDTAVYYCAADYSGSY TSLWSRPERLDWGQGTQVTVFS
22-4L- 16	5	QVQLVESGGGLVQAGGSLRLSCAASGRFTFSYAMGWFRQAPGKREFVAAIS WSGGSTYYADSVKGRFTISRDNKNTVYLQMNSLKPEDTAVYYCVADTGGIS WIRTQGYNYWGQGTQVTVSS
T76	6	QVQLQESGGGLVQPGESLRLSCAASGSIFSINTMGWYQAPGKQRELVASIT FGGVNTYADSVKGRFTISRDNNTDTVYLQMNSLKPEDTAVYICNAVTVGGGLT NYWGQGTQVTVSS
AM-4- 15-3	7	QVQLQDSGGGLVQPGGSLRLSCAASGSIFSINSMGWYRQAPGKQRELVAHAL ADGSASYRDSVKGRFTISRDNKNTVYLQMNSLKPEDTAVYYCNTVPSSVTK GYWGQGTQVTVSS
		Anti-vWF A3 domain VHH: bivalent or bispecific
AM-4- 15- 3/AM- 4-15-3	8	QVQLQDSGGGLVQPGGSLRLSCAASGSIFSINSMGWYRQAPGKQRELVAHAL ADGSASYRDSVKGRFTISRDNKNTVYLQMNSLKPEDTAVYYCNTVPSSVTK GYWGQGTQVTVSSEPKTPKPQAAAQVQLQDSGGGLVQPGGSLRLSCAASGS IFSINSMGWYRQAPGKQRELVAHALADGSASYRDSVKGRFTISRDNKNTVY LQMNSLKPEDTAVYYCNTVPSSVTKGYWGQGTQVTVSS
AM-4- 15- 3/AM- 2-75	9	QVQLQDSGGGLVQPGGSLRLSCAASGSIFSINSMGWYRQAPGKQRELVAHAL ADGSASYRDSVKGRFTISRDNKNTVYLQMNSLKPEDTAVYYCNTVPSSVTK GYWGQGTQVTVSSEPKTPKPQAAAQVQLQESGGGLVQPGGSLRLSCAASGF NFWYPMWVRQAPGKGLEWVSTISTYGEPRYADSVKADSPSETTPTTRCI CNEQPETEDTAVYYCARGAGTSSYLPQRGWWDQGTQVTVSS
AM-2- 75/AM- 4-15-3	10	QVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNANNTLYLQMNSLRPEDTAVYYCARGAGTSSY LPQRGWWDQGTQVTVSSEPKTPKPQAAAQVQLQDSGGGLVQPGGSLRLSCA ASGSIFSINSMGWYRQAPGKQRELVAHALADGSASYRDSVKGRFTISRDNK

		NTVYLQMNSLKPEDTAVYYCNTVPSSVTKGYWGQGTQVTVSS
AM-2-75/AM-2-75	11	QVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMSWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNANNTLYLQMNSLRPEDTAVYYCARGAGTSSY LPQGRNWDQGTQVTVSSQVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMS WVRQAPGKGLEWVSTISTYGEPRYADSVKGRFTISRDNANNTLYLQMNSLRP EDTAVYYCARGAGTSSYLPQGRNWDQGTQVTVSS
AM-2-75/22-4L-16	12	QVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMSWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNANNTLYLQMNSLRPEDTAVYYCARGAGTSSY LPQGRNWDQGTQVTVSSEPKTPKPQPAQAQVQLVESGGGLVQAGGSLRLS ASGRFTSSYAMGWFRQAPGKEREFVAAISWSGGSTYYADSVKGRFTISRDN KNTVYLQMNSLKPEDTAVYYCVADTGGISWIRTQGYNYWGQGTQVTVSS
		Anti-vWF VHH + anti-mouse serum albumin VHH
MSA21/AM-2-75	13	QVQLQESGGGLVQPGGSLRLSCEASGFTFSRFGMTWVRQAPGKGVWVSGIS SLGDSTLYADSVKGRFTISRDNANNTLYLQMNSLKPEDTAVYYCTIGGSLNPG GQGTQVTVSSEPKTPKPQPAQAQVQLQESGGGLVQPGGSLRLSCEASGFNFW YPMWSWVRQAPGKGLEWVSTISTYGEPRYADSVKADSPSETPTPTTRCICNE QPETEDTAVYYCARGAGTSSYLPQGRNWDQGTQVTVSS
MSA21/AM-4-15-3	14	QVQLQESGGGLVQPGGSLRLSCEASGFTFSRFGMTWVRQAPGKGVWVSGIS SLGDSTLYADSVKGRFTISRDNANNTLYLQMNSLKPEDTAVYYCTIGGSLNPG GQGTQVTVSSEPKTPKPQPAQAQVQLQDSGGGLVQPGGSLRLACAASGSIFS INSMGWYRQAPGKQRELVAHALADGSASYRDSVKGRFTISRDNANNTVYLQ MSLKPEDTAVYYCNTVPSSVTKGYWGQGTQVTVSS
MSA21/22-4L-16	15	QVQLQESGGGLVQPGGSLRLSCEASGFTFSRFGMTWVRQAPGKGVWVSGIS SLGDSTLYADSVKGRFTISRDNANNTLYLQMNSLKPEDTAVYYCTIGGSLNPG GQGTQVTVSSEPKTPKPQPAQAQVQLVESGGGLVQAGGSLRLSCEASGRFTS SYAMGWFRQAPGKEREFVAAISWSGGSTYYADSVKGRFTISRDNANNTVYLQ MNSLKPEDTAVYYCVADTGGISWIRTQGYNYWGQGTQVTVSS
		Anti-mouse serum albumin VHH
MSA21	16	QVQLQESGGGLVQPGGSLRLSCEASGFTFSRFGMTWVRQAPGKGVWVSGIS SLGDSTLYADSVKGRFTISRDNANNTLYLQMNSLKPEDTAVYYCTIGGSLNP GGQGTQVTVSS
MSA24	17	QVQLQESGGGLVQPGNSLRLSCEASGFTFRNFGMSWVRQAPGKEPEWVSSIS GSGSNTIYADSVKDRFTISRDNANNTLYLQMNSLKPEDTAVYYCTIGGSLSR SSQGTQVTVSS
MSA210	18	QVQLQESGGGLVQPGGSLRLTCTASGFTFSFGMSWVRQAPGKGLEWVSAIS SDSGTKNYADSVKGRFTISRDNANNTLYLQMNSLRPEDTAVYYCVIGRGSPS SQGTQVTVSS
MSA212	19	QVQLQESGGGLVQPGGSLRLTCTASGFTFRSFGMSWVRQAPGKGLEWVSAIS ADGSDKRYADSVKGRFTISRDNANNTLYLQMNSLKPEDTAVYYCVIGRGSPA SQGTQVTVSS
MSAcl6	49	AVQLVESGGGLVQAGDSLRLSCVSGTTFSSAAMGWFRQAPGKEREFVGAIK WSGTSTYYTDSVKGRFTISRDNANNTVYLQMNSLKPEDTGVYTCAADRDRYR DRMGPMTTTDFRFGQGTQVTVSS

MSAc11 2	50	QVKLEESGGGLVQTGGSLRLSCAASGRFTSFSSFAMGWFRQAPGREREFVASIG SSGITTNADSVKGRFTISRDNKNTVYLQMNLSKPEDTGLCYCAVNRYGIP YRSGTQYQNWGGGTQVTVSS
MSAc11 0	51	EVQLEESGGGLVQPGGSLRLSCAASGLTFNDYAMGWYRQAPGKERDMVATIS IGGRITYADSVKGRFTISRDNKNTVYLQMNLSKPEDTAIYYCAVHRQTVVR GPYLLWGGGTQVTVSS
MSAc11 4	52	QVQLVESGGGLVQAGGSLRLSCAASGRFTFSNYAMGWFRQAPGKEREFVAGSG RSNSYNYSDSVKGRFTISRDNKNTVYLQMNLSKPEDTAVYYCAASTNLWP RDRNLYAYWGGGTQVTVSS
MSAc11 6	53	EVQLVESGGGLVQAGDSLRLSCAASGRSLGIYRMGWFRQVPGKEREFVAAIS WSGGTTRYLDSVKGRFTISRDKNAVYLQMNLSKPEDTAVYYCAVDSSGRL YWTLSYDYWGGGTQVTVSS
MSAc11 9	54	QVQLVEFGGGLVQAGDSLRLSCAASGRSLGIYKMAWFRQVPGKEREFVAAIS WSGGTTRYIDSVKGRFTISRDNKNTVYLQMNLSKPDDTAVYYCAVDSSGRL YWTLSYDYWGGGTQVTVSS
MSAc15	55	EVQLVESGGGLVQAGGSLRLSCAASGRFTSPYTMGWFRQAPGKEREFVAGVT WSGSSTFYGDSVKGRFTASRDSAKNTVTLEMNLSNPEDTAVYYCAAAYGGGL YRDPRESYDYWGRGTQVTVSS
MSAc111	56	AVQLVESGGGLVQAGGSLRLSCAASGFTLDAPFIWFRQAPGKEREGVSCIR DGTITYADSVKGRFTISSDNANNTVYLQTNLSKPEDTAVYYCAAPSGPATGS SHTFGIYNLRDDYDNWGGGTQVTVSS
MSAc11 5	57	EVQLVESGGGLVQAGGSLRLSCAASGFTFDHYTIGWFRQVPGKEREGVSCIS SSDGSTYYADSVKGRFTISSDNKNTVYLQMNLTLEPDDTAVYYCAAGGLLLR VEELQASDYDYWGGGIQVTVSS
MSAc18	58	AVQLVDSGGGLVQPGGSLRLSCTASGFTLDYYAIGWFRQAPGKEREGVACIS NSDGSTYYGDSVKGRFTISRDNKNTVYLQMNLSKPEDTAVYYCATADRHYS ASHHPFADFANWGGGTQVTVSS
MSAc17	59	EVQLVESGGGLVQAGGSLRLSCAAYGLTFWRAAMAWFRAPGKERELVARN WGDGSTRYADSVKGRFTISRDNKNTVYLQMNLSKPEDTAVYYCAAVRTYGS ATYDIWGGGTQVTVSS
MSAc12 0	60	EVQLVESGGGLVQDGGSLRLSCIFSGRTFANYAMGWFRQAPGKEREFVAAIN RNGGTTNYADALKGRFTISRDNKNTAFLQMNLSKPDDTAVYYCAAREWPFS TIPSGWRYWGGGTQVTVSS
MSAc14	61	DVQLVESGGGWVQPGGSLRLSCAASGPTASSHAIGWFRQAPGKEREFVGIN RGGVTRDYADSVKGRFAVSRDNVKNVYLQMNRLKPEDSAIYICARPEYSF TAMSKGDMDYWGKGTLVTVSS
Anti vWF A1 domain VHH + anti vWF A3 domain VHH		
2A1- 4L- 79/AM- 4-15-3	20	QVQLQDSGGRLVKAGASLRLSCAASGRFTFSSLPMAWFRQAPGKEREFVAFIG SDSSTLYTSSVRGRFTISRDNKNTVYLQMMNLKPEDTAVYYCAARSSAFSS GIYYREGSYAYWGGGTQVTVSSSEPKTPKPQAAAQVQLQDSGGGLVQPGGSL RLACAASGSIFSINSMGWYRQAPGKQRELVAHALADGSASYRDSVKGRFTIS RDNKNTVYLQMNLSKPEDTAVYYCNTVPSSVTKGYWGGGTQVTVSS
2A1- 4L- 79/AM- 2-75	21	QVQLQDSGGRLVKAGASLRLSCAASGRFTFSSLPMAWFRQAPGKEREFVAFIG SDSSTLYTSSVRGRFTISRDNKNTVYLQMMNLKPEDTAVYYCAARSSAFSS GIYYREGSYAYWGGGTQVTVSSSEPKTPKPQAAAQVQLQESGGGLVQPGGSL RLSCAASGFNFNWPMSWVRQAPGKLEWVSTISTYGEPRYADSVKADSPSS ETTPTRCICNEQPETEDTAVYYCARGAGTSSYLPQRGNWDQGTQVTVSS
2A1- 4L- 79/22-	22	QVQLQDSGGRLVKAGASLRLSCAASGRFTFSSLPMAWFRQAPGKEREFVAFIG SDSSTLYTSSVRGRFTISRDNKNTVYLQMMNLKPEDTAVYYCAARSSAFSS GIYYREGSYAYWGGGTQVTVSSSEPKTPKPQAAAQVQLVESGGGLVQAGGSL

4 L-16		RLSCAASGRTFSSYAMGWFRQAPGKEREVFAAISWSGGSTYYADSVKGRFTI SRDNAKNTVYLQMNSLKPEDTAVYYCVADTGGISWIRTQGYNYWGQGTQVTV SS
Anti vWF A1 domain VHH		
A50	23	QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYRMGWFRQAPGKEREVFAAIS RRGDNVYYADSVKGRFAISRDNASTLYLQMNSLKPEDTAVYYCAAHVTVSA ITLSTSTYDYWGQGTQVTVSS
I53	24	QVQLQDSGGGLVQAGGSLRLSCAASGRTKDMAWFRQPPGKEREVFAVIYSSD GSTLVAASVKGRFTISRDNKNTVYLQMTSLKPADTAVYYCATSRGYSGETYY STSRDYWTGGTQVTVSS
Z29	25	QVQLQESGGGSVQAGDSLTLSCAASGRTFSMHAMGWFRQAPGKEREVFAAIS PSAFTEYADSLKGRFTVSRDNAKKLVWLQMNLKPEDTAAYYCAARRGAFTA TTAPLYDYWGQGTQVTVSS
M53	26	QVQLQDSGGGLVQAGESLRLSCGTSGRFTFGRRAMAWFRQAPGKERQFVAWIA RYDGSTLYADSVKGRFTISRDDNKNTMYLHMNNLTPEDTAVYYCAAGPRGLY YESRYEYWGQGTQVTVSS
2A1- 4L-79	27	QVQLQDSGGRLVKAGASLRLSCAASGRTFSSLPMAWFRQAPGKEREVFAFIG SDSSTLYTSSVRGRFTISRDNKNTVYLQMMNLKPEDTAVYYCAARSSAFSS GIYYREGSYAYWGQGTQVTVSS
2A1- 4L-129	28	QVQLQESGGGLVQAGASLRLSCAASGRSFSSYPMAWFRQAPGKEREVVFVFIG SDHSTLYSTSVRGRFTISRDNKNTVYLQMMNLKPEDTAVYYCAARNSAWSS GIYYRETSYDYWGQGTQVTVSS
2A1- 4L-34	29	QVQLQDSGGGSVQAGASLRLSCAASGGTFSSYAMAWFRQAPGKEREVFGFIG SDGSTLYSSSVRGRFTISRDNKNTVALQMMNLKPEDTAVYYCAARARYSGI YYRETDYPYWGQGTQVTVSS
2A1- 4L-78	30	QVQLQESGGGLVQAGASLRLSCTASGRSFGGFPMGWFRQAPGKEREVFSGLT RSLFTVYADSVKGRFTVSTDNKNTVYLQMNSLKPEDTAVYYCAARPDLAY SRDPNEYDYWGQGTQVTVSS
2LA1- 15	31	QVQLQDSGGGLVQSGGSLRLACAASGRIVSTYAMGWFRQSPGKEREVATVK GRFTISRDNKNTLYLQMNSLKPEDTAVYYCAKTKRTGIFTTARMVDYWGQ GTQVTVSS
Anti vWF A1 domain VHH, bispecific and bivalent VHH		
2A1- 4L- 79/2A1 -4L-79	32	QVQLQDSGGRLVKAGASLRLSCAASGRTFSSLPMAWFRQAPGKEREVFAFIG SDSSTLYTSSVRGRFTISRDNKNTVYLQMMNLKPEDTAVYYCAARSSAFSS GIYYREGSYAYWGQGTQVTVSSSEPKTPKPQAAAQVQLQDSGGRLVKAGASL RLSCAASGRTFSSLPMAWFRQAPGKEREVFAFIGSDSSTLYTSSVRGRFTIS RDNGKNTVYLQMMNLKPEDTAVYYCAARSSAFSSGIYYREGSYAYWGQGTQV TVSS
2LA1- 15/2LA 1-15	33	QVQLQDSGGGLVQSGGSLRLACAASGRIVSTYAMGWFRQSPGKEREVATVK GRFTISRDNKNTLYLQMNSLKPEDTAVYYCAKTKRTGIFTTARMVDYWGQ GTQVTVSSSEPKTPKPQAAAQVQLQDSGGGLVQSGGSLRLACAASGRIVSTYA MGWFRQSPGKEREVATVKGRFTISRDNKNTLYLQMNSLKPEDTAVYYCAK TKRTGIFTTARMVDYWGQGTQVTVSS
A50/A5 0	34	QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYRMGWFRQAPGKEREVFAAIS RRGDNVYYADSVKGRFAISRDNASTLYLQMNSLKPEDTAVYYCAAHVTVSA ITLSTSTYDYWGQGTQVTVSSSEPKTPKPQAAAQVQLQESGGGLVQAGGSLR LSCAASGRTFSSYRMGWFRQAPGKEREVFAAISRRGDNVYYADSVKGRFAIS RDNAESTLYLQMNSLKPEDTAVYYCAAHVTVSAITLSTSTYDYWGQGTQVTV SS
Anti collagen VHH		

3P1-31	35	QVQLQESGGGLVQAGGSLRLSCAASGRTFRRYAMGWYRQAPGKQRELVAAIT SGGRTSVADTVKGRFTISSDNAKNTVYLQMNSLKPEDAAVYYCTLYNSTTNY YNQSPSSWGQGTQVTVSS
3L-41	36	QVQLQDSGGGLVQAGGSLRLSCAASGRTFRRYAMGWYRQAPGKQRLVAAIT SNGRPSVADSVKGRFTISSDTAKNTVYLQMNSLKPEDTALYYCTLYNTSADY YNQSPSSWGQGTQVTVLS
3P2-31	37	QVQLQESGGGLVQAGDSLRLSCAASGRTFTMGWFRQAPGKERQFVAALTWG GSPVYADSVKGRFTTWRVLDNNTVYLHMNSLKPEDTAVYHCAAARTYYGNIS EYYDYWGQGTQVTVSS
		Anti-vWF VHH: humanized
C37-3	38	QVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARGAGTSSY LPQRGWWDQGTQVTVSS
C37-4	39	QVQLQESGGGLVQPGGSLRLSCAASGFNFWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKGAGTSSY LPQRGWWDQGTQVTVSS
C37-8	40	EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKGAGTSSY LPQRGWWDQGTQVTVSS
C37-10	41	EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYPMWVRQAPGKGLEWVSTIS TYGEPYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKGAGTSSY LPQRGWWDQGTQVTVSS
		Humanised anti-vWF VHH + anti-mouse serum albumin VHH
MSA21/ C37- hum	42	QVQLQESGGGLVQPGGSLRLSCEASGFTFSRFGMTWVRQAPGKGVVSGIS SLGDSTLYADSVKGRFTISRDNKNTLYLQMNSLKPEDTAVYYCTIGGSLNP GGQGTQVTVSSEPKTPKPQAAAQVQLQESGGGLVQPGGSLRLSCAASGFTF SWYPMWVRQAPGKGLEWVSTISTYGEPRYADSVKGRFTISRDNKNTLYLQ MNSLRAEDTAVYYCAKGAGTSSYLPQRGWWDQGTQVTVSS
MSA24/ C37- hum	43	QVQLQESGGGLVQPGNSLRLSCAASGFTFRNFGMSWVRQAPGKEPEWVSSIS GSGSNTIYADSVKDRFTISRDNKNTLYLQMNSLKPEDTAVYYCTIGGSLSR SSQGTQVTVSSEPKTPKPQAAAQVQLQESGGGLVQPGGSLRLSCAASGFTF SWYPMWVRQAPGKGLEWVSTISTYGEPRYADSVKGRFTISRDNKNTLYLQ MNSLRAEDTAVYYCAKGAGTSSYLPQRGWWDQGTQVTVSS
MSA210 / C37- hum	44	QVQLQESGGGLVQPGGSLRLTCTASGFTFSFSGMSWVRQAPGKGLEWVSAIS SDSGTKNYADSVKGRFTISRDNKNTLYLQMNSLKPEDTAVYYCVIGRGSPS SQGTQVTVSSEPKTPKPQAAAQVQLQESGGGLVQPGGSLRLSCAASGFTFS WYPMWVRQAPGKGLEWVSTISTYGEPRYADSVKGRFTISRDNKNTLYLQ MNSLRAEDTAVYYCAKGAGTSSYLPQRGWWDQGTQVTVSS
MSA212 / C37- hum	45	QVQLQESGGGLVQPGGSLRLTCTASGFTFSFSGMSWVRQAPGKGLEWVSAIS ADGSDKRYADSVKGRFTISRDNKNTLYLQMNSLKPEDTAVYYCVIGRGSPA SQGTQVTVSSEPKTPKPQAAAQVQLQESGGGLVQPGGSLRLSCAASGFTFS WYPMWVRQAPGKGLEWVSTISTYGEPRYADSVKGRFTISRDNKNTLYLQ MNSLRAEDTAVYYCAKGAGTSSYLPQRGWWDQGTQVTVSS

		Anti collagen VHH: bispecific
3P1- 31/3P2 -31	46	QVQLQESGGGLVQAGGSLRLSCAASGRTFRRYAMGWYRQAPGKQRELVAAIT SGGRTSVADTVKGRFTISSDNAKNTVYLQMNSLKPEDAAVYYCTLYNSTTNY YNQSPSSWGQGTQVTVSSEPKTPKPQPAQAQVQLQESGGGLVQAGDSLRLSC AASGRTFTMGWFRQAPGKERQFVAALTWGGSPVYADSVKGRFTTWRVLDNN TVYLHMNSLKPEDTAVYHCAAARTYYGNISEYYDYWGQGTQVTVSS
3L- 41/3P2 -31	47	QVQLQDSGGGLVQAGGSLRLSCAASGRTFRRYAMGWYRQAPGKQRLVAAIT SNGRPSVADSVKGRFTISSDTAKNTVYLQMNSLKPEDTALYYCTLYNTSADY YNQSPSSWGQGTQVTVLSEPKTPKPQPAQAQVQLQESGGGLVQAGDSLRLSC AASGRTFTMGWFRQAPGKERQFVAALTWGGSPVYADSVKGRFTTWRVLDNN TVYLHMNSLKPEDTAVYHCAAARTYYGNISEYYDYWGQGTQVTVSS
		Human vWF
Human vWF	48	MIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYS FAGYCSYLLAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQ GDQRVSMYPYASKGLYLETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFN KTCGLCGNFNIFAEDDFMTQEGTLTSDPYDFANSWALSSGEQWCERASPPSS SCNISSGEMQKGLWEQCQLLKSTSVFARCHPLVDPEPFVALCEKTLCECAGG LECACPALLEYARTCAQEGMVLYGWTDHSA CSPVCPAGMEYRQCVPSPCARTC QSLHINEMCQERCVDGCSCEGQLLDEGLCVESTECPCVHSGKRYPPGTSLS RDCNTCICRNSQWICSNEECPEGCLVTGQSHFKSFDNRYFTFSGICQYLLAR DCQDHSFSIIVETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDG QDIQLPLLLKGDRLRIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKT CGLCGNYNGNQDDFLTPSGLAEPRVEDFGNAWKLHGDCQDLQKQHSDEPCAL NPRMTRFSEEACAVLTSPTFEACHRAVSPLPYLRNCRYDVCSCSDGRECLCG ALASYAAACAGRGVRVAWREPGRCNELNCPKGQVYLQCGTPCNLTCSRSLSPD EECNEACLEGCFCPPGLYMDERGDVPAQCPCYDGEIFQPEDIFSDHHTM CYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSRPPMVKLVCADN LRAEGLECTKTCQNYDLECMGCVSGCLCPPGMVRHENRCVALERCPCFHHQ GKEYAPGETVKIGCNTCVCRRDKWNCTDHVCDATCSTIGMAHYLTFDGLKYL FPGECQYVLVQDYCGSNPGTFRILVGNKGCSHPSVKCKKRVITILVEGGEIEL FDGEVNVKRPMDETHFEVVESEGRYIILLGKALS VVWDRHLSISVVLKQTY QEKVCGLCGNFDGIQNDLTSSNLQVEEDPVDGNSWKVSSQCADTRKVPLD SSPATCHNNIMKQTMVDSSCRILTSDFVQDCNKLVDPEPYLDVCIYDTCSE SIGDCACFCDTIAAYAHVCAQHGVVWTRTATLCPQSCERNLRENGYECWE RYNSCAPACQVTCQHPEPLACPVCQVEGCHACPPGKILDELLQTCVDPEDC PVCCEVAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPT DAPVSPTTLYVEDISEPPLHDFYCSRLDLVFLLDGSSRLSEAEFEVLKAFV VDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSRLRRIASQVKYAGS QVASTSEVLKYLTFQIFSKIDRPEASRIALLMASQEPQRMRSRNFVRVYQGL KKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVLSSVDELEQQRDEIVSY LCDLAPEAPPPTLPPHMAQVTVGPGLRNSMVLDVAFVLEGS DKIGEADFNRS KEFMEEVIQRMDVGQDSIHVTVLQYSYMTVEYPFSEAQSKGDILQVRREIR YQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMTGNPASDEIKRLPG DIQVPIGVGPANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGE GLQIPTLSAPDCSQPLDVILLLDGSSSFASYFDEMKSFAKAFISKANIGP RLTQVSVLQYGSITTIDVPWNVPEKAHLLSLVDVMQREGGPSQIGDALGFA VRYLTSEMHGARGASKAVVILVTDVSVDSVDAADAARSNRVTVFPIGID RYDAAQLRILAGPAGDSNVVKLQRIEDLPTMVTLGNSFLHKLCSGFVRICMD EDGNEKRPBGDVWTLPDQCHTIVTCQPDGQTLLKSHRVNCDRGLRSPCNSQSP VKVEETCGCRWTCPCVCTGSSTRHIVTFDGNFKLTGSCSYVLFQNKQDLE

		<p> VILHNGACSPGARQGC MKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGN MEVNVYGAIMHEVRFNHLGHIFTFTPQNNFQLQLSPKTFASKTYGLCGICD ENGANDFMLRDGTVTDDWKT LVQEWTVQRPQGTCPILEEQCLVPDSSHCQV LLLPLFAECHKVLAPATFYAICQQDSCHQEQVCEVIASIAHLCRTNGVCVDW RTPDFCAMS CPPSLVYNHCEHGCPRHCDGNVSSCGDHPSEGCF CPPDKVMLE GSCVPEEACTQCIGEDGVQHGFLEAWVPDHPQCQICTCLSGRKVNCTTQPCP TAKAPTCGLCEVARLRQADQCCPEYECVCDPVSCDLPPVPHCERGLQPTLT NPGECRPNFTCACRKEECKRVSPSCPPHRLPTLRKTQCCDEYECACNCVNS TVSCPLGYLASTATND CGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTC TDMEDAVMGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGS PRGDSQSSWKS VGSQWASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVC PSGFQLSCKTSACCPSCRCERMEACMLNGTVIGPGKTMIDVCTTCRCMVQV GVISGFKLECRKTT CNPCPLGYKEENNTGECCGRCLPTACTIQLRGGQIMTL KRDETLQDGC DTHFCKVNERGEYFWEKRV TGCPPFDEHKCLAEGGKIMKIPG TCCDTCEEPECNDITARLQYVKVG SCKSEVEVDIHYCQGKCASKAMYSIDIN DVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK </p>
--	--	--

CLAIMS

1. A polypeptide construct comprising:
 - at least one single domain antibody directed against any of vWF, vWF A1 domain, vWF A3 domain, gpIb, or collagen.
2. A polypeptide construct according to claim 1, further comprising at least one single domain antibody directed against one or more serum proteins.
3. A polypeptide construct according to claim 2 wherein said at least one serum protein is any of serum albumin, serum immunoglobulins, thyroxine-binding protein, transferrin, or fibrinogen or a fragment thereof.
4. A polypeptide construct according to claims 2 and 3, wherein at least one single domain antibody directed against one or more serum proteins corresponds to a sequence represented by any of SEQ ID NO: 16 to 19 and 49 to 61.
5. A polypeptide construct according to any of claims 2 to 4 corresponding to a sequence represented by any of SEQ ID NOs: 13 to 15 and 42 to 45.
6. A polypeptide construct according to claim 1 to 5 wherein at least one single domain antibody is a humanised sequence.
7. A polypeptide construct according to claim 6 wherein at least one single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 38 to 41 and 42 to 45.
8. A polypeptide construct according to claim 1 corresponding to a sequence represented by any of SEQ ID NOs: 8 to 12, 20 to 22, 32 to 34, and 42 to 47.
9. A polypeptide construct according to any of claims 1 to 8 wherein at least one single domain antibody is a *Camelidae* VHH antibody.

10. A polypeptide construct according to any of claims 1 to 9 wherein at least one single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 1 to 7, 23 to 31, and 35 to 37.
- 5 11. A polypeptide construct according to any of claims 1 to 10, wherein said single domain antibody is an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length single domain antibody.
- 10 12. A polypeptide construct according to any of claims 1 to 11, wherein said polypeptide construct is a homologous sequence of said polypeptide construct, a functional portion thereof, of an homologous sequence of a functional portion thereof.
13. A nucleic acid encoding a polypeptide construct according to any of claims 1 to 12.
- 15 14. A composition comprising a polypeptide construct according to any of claims 1 to 12 and at least one thrombolytic agent, for simultaneous, separate or sequential administration to a subject.
- 20 15. A composition according to claim 14 wherein said thrombolytic agent is any of staphylokinase, tissue plasminogen activator, streptokinase, single chain streptokinase, urokinase and acyl plasminogen streptokinase complex.
- 25 16. A polypeptide construct according to any of claims 1 to 12, or a nucleic acid according to claim 13, or a composition according to claims 14 and 15 for use in the treatment, prevention and/or alleviation of disorders relating to platelet-mediate aggregation or dysfunction thereof.
- 30 17. Use of a polypeptide construct according to any of claims 1 to 12, or a nucleic acid according to claim 13, or a composition according to claims 14 and 15 for the preparation of a medicament for the treatment, prevention and/or alleviation of disorders relating to platelet-mediate aggregation or dysfunction thereof.
18. A polypeptide construct, nucleic acid or composition according to claim 16 or a use of a polypeptide construct, nucleic acid or composition according to claim 17 wherein said

disorders are any arising from arising from transient cerebral ischemic attack, unstable or stable angina, angina pectoris, cerebral infarction, myocardial infarction, peripheral arterial occlusive disease, restenosis, coronary by-pass graft, or coronary artery valve replacement and coronary interventions such angioplasty, stenting, carotid endarterectomy or
5 atherectomy.

19. A polypeptide construct, nucleic acid or composition according to claim 16 or a use of a polypeptide construct, nucleic acid or composition according to claim 17 wherein said disorders are any of the formation of a non-occlusive thrombus, the formation of an occlusive
10 thrombus, arterial thrombus formation, acute coronary occlusion, restenosis, restenosis after PCTA or stenting, thrombus formation in stenosed arteries, hyperplasia after angioplasty, atherectomy or arterial stenting, occlusive syndrome in a vascular system or lack of patency of diseased arteries.

15 20. A polypeptide construct, nucleic acid or composition according to claim 16 or a use of a polypeptide construct, nucleic acid or composition according to claim 17 wherein said disorder is plaque or thrombus formation in high sheer environments.

21. A polypeptide construct, nucleic acid or composition according to any of claims 16, 18 to
20 20 or a use of a polypeptide construct according to claim 17 to 20 wherein said polypeptide construct is administered intravenously, subcutaneously, orally, sublingually, topically, nasally, vaginally, rectally or by inhalation.

22. A composition comprising a polypeptide construct according to any of claims 1 to 12, 16,
25 18 to 21 or a nucleic acid encoding said polypeptide construct, or a composition according to claims 14 and 15 and a pharmaceutically acceptable vehicle.

23. A method of producing a polypeptide according to any of claims 1 to 12, 16, 18 to 21, comprising
30 (a) culturing host cells comprising nucleic acid capable of encoding a polypeptide according to any of claims 1 to 12, 16, 18 to 21 under conditions allowing the expression of the polypeptide, and,
(b) recovering the produced polypeptide from the culture.

24. A method according to claim 23, wherein said host cells are bacterial or yeast.

25. A method for treating invasive medical devices to prevent platelet-mediate aggregation around the site of invasion comprising the step of coating said device with a polypeptide
5 construct according to claims 1 to 12.

26. An invasive medical device for circumventing platelet-mediate aggregation around the site of invasion, wherein said device is coated with a polypeptide construct according to claims 1
10 to 12.

27. A method of identifying an agent that modulates platelet-mediated aggregation comprising

(a) contacting a polypeptide construct according to claims 1 to 12 with a polypeptide corresponding to its target, or a fragment thereof, in the presence and absence of a candidate
15 modulator under conditions permitting binding between said polypeptides, and

(b) measuring the binding between the polypeptides of step (a), wherein a decrease in binding in the presence of said candidate modulator, relative to the binding in the absence of said candidate modulator identified said candidate modulator as an agent that modulate
20 platelet-mediated aggregation.

28. A kit for screening for agents that modulate platelet-mediated aggregation according to the method of claim 27.

29. An unknown agent that modulates platelet-mediated aggregation identified according to
25 the method of claim 27.

30. A method of diagnosing a disease or disorder characterised by dysfunction of platelet-mediated aggregation comprising the steps of:

(a) contacting a sample with a polypeptide construct according to claims 1 to 12, and
30 (b) detecting binding of said polypeptide construct to said sample, and
(c) comparing the binding detected in step (b) with a standard, wherein a difference in binding relative to said sample is diagnostic of a disease or disorder characterised by dysfunction of platelet-mediated aggregation.

31. A kit for screening for diagnosing a disease or disorder characterised by dysfunction of platelet-mediated aggregation according to the method of claim 30.

5 32. A kit according to claim 28 or 31 comprising a polypeptide construct according to any of claims 1 to 12.

**ABSTRACT**

The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, vWF A3 domain, gplb and/or collagen, homologues
5 of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-
10 mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation

1/17

Figure 1






Figure 2



2/17

Figure 3



3/17

Figure 4




Figure 5



4/17

figure 6


HindIII
1 aagcttgcac gcaaattcta tttcaaggag acagtcataa tgaaatacct attgcctacg gcagccgctg gattgttatt
M K Y L L P T A A A G L L L
pelB-leader

SfiI *NcoI* *NotI* *PstI*
81 actcgcggcc cagccggcca tggggcctaa taggcggcgc cacaggtgca gctgcaggag tcataatgag ggacccaggt
L A A Q P A M G P - - A A A Q V Q L Q E S - - G T Q V
Leader >< VHH#1 > < VHH#2

BstEII
161 caccgtctcc tcagaacaaa aactcatctc agaagaggat ctgaatgggg ccgcacatca tcataatcat cattaatgag
T V S S E Q K L I S E E D L N G A A H H H H H - -
>< C-MYC > < His6 >

EcoRI
241 aattcactgg ccg

Figure 7



5/17

Figure 8




Figure 9





Figure 10



6/17

Figure 11



7/17

Figure 12





Figure 13



8/17

Figure 14






Figure 15



9/17

Figure 16



10/17

Figure 17





Figure 18



11/17

Figure 19






Figure 20




12/17

Figure 21



13/17

Figure 22



14/17

Figure 23






Figure 24



15/17

Figure 25



16/17

Figure 26




Figure 27

DP-47 EVQLLES~~GGGLVQPGGSLRL~~SCAASGFTFS SYAMS WVRQAPGKGLEWVS AISGSGGSTYY
 C-37 QVQLQES~~GGGLVQPGGSLRL~~SCAASGFNFN WYPMS WVRQAPGKGLEWVS TISTYGEPRY-
 DP-47 ADSVKG RFTISRDN~~SKNTLYLQMN~~SLRAEDTAVYYCAK -----
 C-37 ADSVKG RFTISRDN~~ANNTLYLQMN~~SLRPEDTAVYYCAR GAGTSSYLPQRGN
 WDQGTQVTISS

17/17

Figure 28

